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ABSTRACT  
Background: Common beta cell–associated single nucleotide polymorphisms (SNPs) 
and hypertension or its treatment might interact in their positive associations with change 
over time in fasting glucose (ΔFG) or incident type 2 diabetes mellitus (T2DM). 
Methods: We pooled data from 3,471 Framingham Offspring Study participants into 6 
~4-yr periods (15,852 person-exams; mean age 52 years, 54% women). We defined three 
hypertension exposures: 1) hypertension vs. no-hypertension; 2) treated vs. untreated 
hypertension; 3) five mutually exclusive anti-hypertension drug categories (beta-
blockers, thiazides, renin-angiotensin system agents, combinations, others) vs. untreated 
hypertension; and two genetic exposures reflecting total beta-cell genetic risk burden: 16 
FG-SNP and 33 T2DM-SNP additive genetic scores. We tested ~4-year mean ΔFG or 
odds of T2DM by hypertension category and per-risk allele change in genetic scores, 
seeking hypertension-by-genetic-score significant (p<0.05) interaction.  
Results: Versus no hypertension, hypertension conferred higher ΔFG (2.6 vs. 1.7 mg/dl; 
p<0.0001) and T2DM risk (OR=2.9; 95% CI 2.8-3.0; p<0.0001). Versus untreated 
hypertension, treated hypertension conferred higher ΔFG (3.4 vs. 3.0 mg/dl; p<0.0001) 
and T2DM risk (OR=1.4; 95% CI 1.3-1.5; p=0.02). Beta-blockers (OR=1.6; 95% CI 1.1-
2.4), combination treatment (OR=1.6; 95% CI 1.1-2.5) and others (OR=2.0; 95% CI 1.4-
2.9) increased T2DM risk (all p<0.02). Genetic scores increased both ~4-yr ΔFG (0.6 
mg/dl per risk allele; p=8.9x10-16) and T2DM risk (~17% per risk allele; p=2.1x10-7). In 
joint models including interaction terms, all hypertension category-by-genetic score 
interaction terms were p>0.05. In joint models without interaction, hypertension  
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(p<0.0001) and FG-SNP or T2DM-SNP genetic scores independently increased ΔFG or 
T2DM risk (both p<0.001).  
Conclusion: Hypertension, hypertension treatment and common FG- and T2DM-SNP 
genetic scores independently predicted ΔFG and T2DM incidence, but did not modify 
each other’s association with ΔFG or T2DM risk.  
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Antecedentes 
Las tasas de prevalencia de la diabetes mellitus tipo 2 y de la hipertensión arterial 
están alcanzando proporciones alarmantes. Se estima que cerca de una tercera parte de la 
población de los países desarrollados es hipertensa, y que alrededor de una quinta parte 
recibe medicación antihipertensiva.  
La hipertensión es un factor que predispone, per se, al desarrollo de la diabetes 
mellitus tipo 2. Adicionalmente, numerosos estudios sugieren que algunos fármacos 
antihipertensivos pueden empeorar el control glucémico e incrementar el riesgo de 
diabetes mellitus tipo 2. Las tiazidas podrían hacerlo mediante la inhibición directa de la 
función de la célula beta pancreática, a través de mecanismos de inflamación, o bien, de 
forma secundaria a la hipopotasemia que inducen. Asimismo, los beta-bloqueantes 
podrían empeorar el metabolismo de los hidratos de carbono disminuyendo la 
sensibilidad a la insulina, favoreciendo la ganancia de peso o mediante cambios en la 
acción que la insulina ejerce a nivel celular.  
De forma opuesta, se preconiza que los fármacos inhibidores del eje renina-
angiotensina-aldosterona, esto es, los inhibidores del enzima de conversión de 
angiotensina (IECA) y los antagonistas del receptor de angiotensina II (ARA-II), podrían 
mejorar el control glucémico y reducir el riesgo de diabetes mellitus tipo 2; mecanismos 
facilitadores podrían ser la kaliuria inducida, el incremento potencial de la perfusión de la 
célula beta o la influencia beneficiosa que dichos fármacos parecen ejercer sobre el estrés 
oxidativo y la adipogénesis. No obstante, no hay pruebas concluyentes e irrefutables que 
apoyen los argumentos arriba mencionados acerca del efecto que los fármacos 
antihipertensivos ejercen sobre el control glucémico y el riesgo de diabetes mellitus tipo 
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2, quizá debido a la limitación que supone el sesgo de la confusión por indicación fuera 
del ámbito de los ensayos clínicos aleatorizados.    
Hasta la fecha, se han descrito cerca de 40 polimorfismos de nucleótido simple 
(“SNPs”) relacionados con el riesgo de padecer diabetes mellitus tipo 2 en estudios de 
asociación a lo ancho del genoma (GWAS), y 16 polimorfismos (8 de los cuales están 
incluidos en esa lista de 40 polimorfismos asociados con el riesgo de padecer diabetes 
mellitus tipo 2) que influyen en los niveles de glucosa basal plasmática. La mayoría de 
estos polimorfismos parecen modificar el control glucémico y el riesgo de padecer 
diabetes mellitus tipo 2 modificando la función de la célula beta pancreática.   
Si bien es aceptado que el factor que supone la presencia de hipertensión y el uso 
de algunos de sus tratamientos, por un lado, y que factores genéticos, por el otro, 
modifican el control glucémico y el riesgo de padecer diabetes mellitus tipo 2, no se sabe 
hasta qué punto la presencia de cualquiera de ellos modifica la acción que el otro factor 
ejerce sobre la glucemia y sobre el riesgo de desarrollar diabetes mellitus tipo 2.  
 Nuestra hipótesis principal fue demostrar que aquellos polimorfismos comunes de 
nucleótido simple (“SNPs”) que se asocian con los niveles de glucosa basal plasmática o 
con el riesgo de sufrir diabetes mellitus tipo 2, y que aparentemente lo hacen a través de 
su influencia sobre la función de la célula beta pancreática, presentaban un efecto de 
interacción con la hipertensión arterial -o sus tratamientos- en la asociación de ésta -o de 
sus tratamientos- con la variación en el tiempo de los niveles de la glucosa basal 
plasmática y con el riesgo de desarrollar diabetes mellitus tipo 2. 
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Métodos y procedimientos   
Población del estudio 
Utilizamos los datos del Estudio de la Descendencia de Framingham. Esta 
población ha sido evaluada mediante exámenes periódicos cada 3-4 años 
aproximadamente, salvo por el lapso entre el primer y el segundo examen (cerca de 8 
años). Para conseguir la homogeneidad en la interpretación de los resultados, los datos 
provenientes de este primer intervalo de tiempo no fueron incluidos. Se dispuso de 
información genética para 3.471 de los participantes. 
Definiciones 
Definimos tres clasificaciones de exposición al factor “hipertensión”: En cada 
examen, clasificamos a los participantes en: 1. hipertensión frente a no hipertensión; 2. 
hipertensión tratada frente a hipertensión no tratada; y 3. los hipertensos tratados fueron 
categorizados en 5 grupos, según los tratamientos antihipertensivos específicos recibidos 
(beta-bloqueantes, tiazidas, IECA/ARA-II, combinaciones de los previos, y “otros”). 
Definimos la hipertensión arterial como la presencia de presión arterial sistólica ≥140 
mm Hg ó diastólica ≥90 mm Hg en el examen físico, o bien, recibir tratamiento 
antihipertensivo. Definimos la diabetes mellitus ante una glucosa basal plasmática ≥ 126 
mg/dl, o bien, recibir tratamiento con antidiabéticos. No usamos la HbA1C para el 
diagnóstico (sólo disponible en los exámenes 5 y 7). El 99% de los casos de diabetes 
mellitus en el Estudio de la Descendencia de Framingham fueron diabetes mellitus tipo 2. 
Analizamos la asociación de hipertensión, hipertensión tratada y las 5 categorías 
específicas de exposición a fármacos antihipertensivos con la variación en el tiempo de 
los niveles de glucosa basal plasmática y el riesgo de desarrollar diabetes tipo 2. 
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Para controlar otros factores de confusión recogimos datos sobre variables 
adicionales: edad (en años), sexo, índice de masa corporal (kg/m2), estado de fumador 
(actual -al menos 1 cigarrillo/día en el último año- frente a no fumador), niveles de 
lipoproteínas plasmáticas de alta densidad (HDL) y triglicéridos (ambos en mg/dl), y el 
consumo de alcohol referido por el propio sujeto.  
Variación genética común asociada a la glucosa basal plasmática y al riesgo 
de sufrir diabetes mellitus tipo 2 
Para evaluar la influencia genética sobre la variación en el tiempo de la glucosa 
basal plasmática, nos servimos de los 16 polimorfismos para los que se ha descrito su 
asociación con la glucosa basal plasmática, dado que todos ellos parecen influir a través 
de su acción sobre la célula beta pancreática. Para analizar el riesgo de diabetes mellitus 
tipo 2, solamente usamos 33 de los 40 polimorfismos para los que se ha descrito su 
asociación con el riesgo de diabetes tipo 2 aparentemente mediado por su acción sobre la 
célula beta pancreática, excluyendo a los polimorfismos en los que se sospecha una 
asociación a través de una resistencia a la acción insulínica. Construimos un “tanteo” 
(“score”) genético aditivo, ponderado según los efectos descritos en la literatura para 
cada polimorfismo, usando los 16 polimorfismos asociados con los niveles de glucosa 
basal plasmática y, de forma similar, un “tanteo” genético aditivo, ponderado, usando los 
33 polimorfismos asociados al riesgo de desarrollar diabetes mellitus tipo 2. Evaluamos 
la asociación del tanteo genético asociado a los niveles de glucosa basal plasmática con la 
variación a ~4 años de la glucosa basal plasmática, y la asociación del tanteo genético 
asociado al riesgo de desarrollar diabetes mellitus tipo 2 con el riesgo a ~4 años de 
aparición de diabetes mellitus tipo 2. 
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Métodos estadísticos 
 Nuestra hipótesis principal fue analizar si los polimorfismos comunes asociados 
con la glucosa basal plasmática o con el riesgo de diabetes mellitus tipo 2, pero 
exclusivamente aquellos que parecen ejercer su influencia a través de la función de la 
célula beta, interaccionan con la hipertensión arterial o con los fármacos antihipertensivos 
en sus asociaciones positivas con: 1) la variación a ~4 años de la glucosa basal plasmática 
(calculada como la diferencia entre el valor al final menos el valor al principio de cada 
período de tiempo) y 2) el riesgo de incidencia a ~4 años de diabetes mellitus tipo 2.   
Para la estadística descriptiva empleamos el test de chi-cuadrado para variables 
categóricas y la prueba T para la comparación de medias en el caso de variables 
cuantitativas. Evaluamos la variación en el tiempo de la glucosa basal plasmática y el 
riesgo de desarrollar diabetes mellitus tipo 2 como una función de la exposición a la 
hipertensión arterial o sus tratamientos y la predisposición genética usando una 
aproximación de regresión “agrupada” o “de fondo común” (“pooled”): agrupamos los 
datos clínicos de los 2.922 participantes no diabéticos de los que se disponía de 
información sobre todas las variables en todos los exámenes en 6 períodos de tiempo 
(exámenes 2-3, 3-4, 4-5, 5-6, 6-7 y 7-8). De esta forma, generamos 15.852 personas-
observaciones pertenecientes a 6 períodos de tiempo, con una longitud media de período 
de tiempo de 4,15 años, a lo largo de un máximo de 28,3 años de seguimiento. Mediante 
esta metodología, la información de cada individuo al inicio de cada período de tiempo 
contribuyó de forma independiente a la información del mismo individuo perteneciente a 
otro período de tiempo, en el que las condiciones de exposición pueden haber cambiado. 
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Este método de regresión produce estimaciones de punto y varianzas similares al método 
de regresión de Cox con el tiempo como variable dependiente. 
Excluimos los casos de diabetes al inicio de cada periodo de observación. Para 
evaluar la variación en el tiempo de la glucosa basal plasmática, excluimos también a los 
pacientes que habían iniciado tratamiento antidiabético durante el periodo de tiempo 
precedente. Usamos el método de ecuaciones estimativas generalizadas (“GEE”) con la 
función de enlace de identidad familiar en modelos ajustados para la edad, el sexo y el 
nivel de glucosa basal plasmática al principio del periodo de tiempo para el análisis de la 
variación en el tiempo de la glucosa basal plasmática. Para el análisis del riesgo de 
desarrollar diabetes mellitus tipo 2, usamos también el método de ecuaciones estimativas 
generalizadas con la función de enlace logit en modelos ajustados para la edad y el sexo.  
Para demostrar un efecto de interacción entre la hipertensión arterial o las 
categorías terapéuticas, por un lado, y los tanteos genéticos, por el otro, que condicionara 
una modificación de la variación en el tiempo de la glucosa basal plasmática o del riesgo 
de desarrollar diabetes mellitus tipo 2 más allá de los efectos principales, incluimos en los 
modelos términos de interacción de primer orden entre hipertensión, hipertensión tratada 
o exposiciones específicas a tratamientos antihipertensivos y cada tanteo genético. Los 
términos de interacción adoptan la forma: variable dependiente =  β0 + βc*covariables + 
β1*E + β2*SNP + β3*E*SNP + ε, donde E representa la exposición a la hipertensión 
arterial o al fármaco y “SNP” denota la contribución genética. El resultado de interés es 
el valor de p para el test: H0: β3 =0. 
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En análisis secundarios especificados a priori, evaluamos modelos conjuntos 
introduciendo las variables, pero sin incluir términos de interacción, para evaluar la 
hipótesis que, en caso que no se demostrara un efecto de interacción, la hipertensión 
arterial o sus tratamientos y los tanteos genéticos se asociaran, de forma independiente, a 
la variación en el tiempo de la glucosa basal plasmática o al riesgo de desarrollar diabetes 
mellitus tipo 2. 
En análisis secundarios adicionales, exploramos las asociaciones en modelos con 
ajustes añadidos para factores asociados al riesgo de desarrollar diabetes mellitus tipo 2 
medidos al principio de cada período (presión arterial media, índice de masa corporal, 
tabaquismo, valores de colesterol HDL y triglicéridos, y consumo de alcohol), para 
descartar que estos factores de confusión explicaran las asociaciones observadas. 
Los análisis estadísticos se realizaron mediante el sistema SAS, versión 9.2. Se 
consideró presente la significación estadística para los términos de interacción o los 
efectos principales ante valores de p<0.05. 
Poder estadístico para detectar interacción hipertensión-tanteo genético y 
exposición a antihipertensivos-tanteo genético 
Tuvimos una potencia estadística del 80%, con un error de tipo I de 0,05 en 
análisis con dos colas, para frecuencias de alelos entre el 20% y el 80%, para poder 
detectar coeficientes de regresión entre 0,04 y 0,05 para el test de interacción entre 
hipertensión y el tanteo genético, y entre 0,10 y 0,12 para el test de interacción entre la 
exposición a beta-bloqueantes y el tanteo genético, en el caso del análisis de la variación 
en el tiempo de la glucosa basal plasmática; y coeficientes de regresión entre 1,07 y 1,08 
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para el test de interacción entre hipertensión y el tanteo genético, y entre 1,19 y 1,23 para 
el test de interacción entre la exposición a beta-bloqueantes y el tanteo genético, en el 
caso del análisis del riesgo de desarrollar diabetes mellitus tipo 2.  
Resultados 
Características basales de la población del estudio 
La media de edad fue de 51,9 años y el 53,8% de la población estaba compuesta 
por mujeres. Con el envejecimiento de la población del estudio, el índice de masa 
corporal aumentó, y tanto la hipertensión como la hipertensión tratada se hicieron más 
prevalentes. Las personas con hipertensión arterial tendían a ser mayores, más 
frecuentemente hombres, con índices de masa corporal más altos y con perfiles lipídicos 
de mayor riesgo que las personas sin hipertensión. Los participantes con hipertensión no 
tratada eran más jóvenes, más frecuentemente hombres, y con valores más elevados de 
presión arterial que sus homólogos tratados. Las diferencias basales entre las diferentes 
exposiciones a antihipertensivos y el grupo de referencia con hipertensión no tratada 
fueron nominalmente significativas para la edad, el sexo, el índice de masa corporal y el 
hábito tabáquico.  
  Asociación entre hipertensión, hipertensión tratada y exposiciones 
específicas a antihipertensivos con la variación en el tiempo de la glucosa basal 
plasmática 
 Frente a la ausencia de hipertensión arterial, el diagnóstico de hipertensión arterial 
se asoció a una variación en el tiempo de la glucosa basal plasmática 0,9 mg/dl mayor 
(p<0,0001). Frente a la hipertensión no tratada, la hipertensión tratada se asoció a una 
variación en el tiempo de la glucosa basal plasmática 0,4 mg/dl mayor (p<0,0001). Frente 
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a la hipertensión no tratada, los IECA/ARA-II (p=0,037) y el tratamiento combinado 
(p=0,046) se asociaron a una mayor variación en el tiempo de la glucosa basal 
plasmática; la asociación de la variación en el tiempo de la glucosa basal plasmática con 
la exposición a beta-bloqueantes y tiazidas no fue estadísticamente significativa.  
 Asociación entre hipertensión, hipertensión tratada y exposiciones específicas 
a antihipertensivos con el riesgo de desarrollar diabetes mellitus tipo 2 
 Frente a la ausencia de hipertensión, el diagnóstico de hipertensión se asoció a 
una probabilidad ~3 veces mayor de desarrollar diabetes mellitus tipo 2 (Odds Ratio 
(OR) = 2,9; 95% CI 2,8-3,0). Frente a la hipertensión no tratada, la hipertensión tratada 
confirió una probabilidad un 40% mayor de desarrollar diabetes mellitus tipo 2 (OR = 
1,4; 95% CI 1,3-1,5). Frente a la hipertensión no tratada, el tratamiento con beta-
bloqueantes (OR=1,6; 95% CI 1,1-2,4), el tratamiento combinado (OR=1,6; 95% CI 1,1-
2,5) y el tratamiento con “otros” (OR=2,0; 95% CI 1,4-2,9) se asociaron a un mayor 
riesgo de desarrollar diabetes mellitus tipo 2.  
 Asociación de los tanteos genéticos aditivos con la variación en el tiempo de 
la glucosa basal plasmática y el riesgo de desarrollar diabetes mellitus tipo 2 
  Los efectos individuales de los polimorfismos genéticos de nucleótido simple en 
la variación en el tiempo de la glucosa basal plasmática y el riesgo de desarrollar diabetes 
mellitus tipo 2, en modelos ajustados para la edad y el sexo, fueron mayoritariamente en 
la misma dirección y de efectos similares a los originalmente descritos en los estudios de 
asociación a lo ancho del genoma. Por alelo genético ponderado de riesgo, la variación en 
el tiempo de la glucosa basal plasmática aumentó 0,55 mg/dl (p=8,9x10-16), y la 
probabilidad de desarrollar diabetes mellitus tipo 2 aumentó un 16,6% (95% CI 10,0-
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23,6), mostrando aquellos sujetos que debutaron con diabetes mellitus tipo 2 tanteos 
genéticos medios más altos que los que no lo hicieron (17,3 vs. 16,8; p=2,1x10-7). 
 Efecto de interacción entre la hipertensión arterial o sus categorías de 
tratamiento y los tanteos genéticos 
 Ninguno de los valores de p en los modelos conjuntos que incluyeron términos de 
interacción para la hipertensión arterial, la hipertensión tratada o los tratamientos con 
fármacos antihipertensivos específicos x tanteos genéticos, prediciendo la variación en el 
tiempo de la glucosa basal plasmática o el riesgo de desarrollar diabetes mellitus tipo 2, 
fue estadísticamente significativo (todas los valores de p>0,3). 
Modelos conjuntos incluyendo hipertensión arterial, la hipertensión tratada o 
los tratamientos con fármacos antihipertensivos específicos y los tanteos genéticos 
sin términos de interacción 
 En los modelos conjuntos sin interacción, la hipertensión arterial, el uso de 
tiazidas y de IECA/ARA-II, pero no la hipertensión tratada o el uso de beta-bloqueantes, 
y el tanteo genético asociado a glucosa basal plasmática predijeron, de forma 
independiente, la variación en el tiempo de la glucosa basal plasmática. En los modelos 
conjuntos sin interacción, la hipertensión arterial, la hipertensión tratada y el tanteo 
genético asociado a diabetes mellitus tipo 2 predijeron, de forma independiente, el riesgo 
de desarrollar diabetes mellitus tipo 2. Ninguna de las exposiciones específicas a 
fármacos antihipertensivos (todos los valores de p>0,19) predijo la incidencia de 
diabetes.  
  Análisis secundarios 
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En análisis secundarios adicionales usando modelos con ajuste adicional para 
factores de confusión de riesgo de desarrollar diabetes mellitus tipo 2, los resultados 
estadísticamente significativos hallados en los modelos con ajuste para edad, sexo, y 
adicionalmente para glucosa basal plasmática en el caso de la variación en el tiempo de la 
glucosa basal plasmática, fueron mayoritariamente reproducidos. 
Conclusiones 
1. En el Estudio de la Descendencia de Framingham, con el envejecimiento de la 
población, el índice de masa corporal aumentó, y tanto la hipertensión como la 
hipertensión tratada se hicieron más prevalentes. 
2. Frente a la ausencia de hipertensión, la hipertensión arterial se asoció a una mayor 
variación en el tiempo (~4 años) de la glucosa basal plasmática y a una mayor 
probabilidad de desarrollar diabetes mellitus tipo 2. 
3. Frente a la hipertensión no tratada, la hipertensión tratada confirió una mayor 
variación en el tiempo (~4 años) de la glucosa basal plasmática y una mayor 
probabilidad de desarrollar diabetes mellitus tipo 2. 
4. El uso de IECA/ARA-II se asoció nominalmente a una mayor variación en el 
tiempo (~4 años) de la glucosa basal plasmática. El uso de beta-bloqueantes se 
asoció nominalmente a una mayor probabilidad de desarrollar diabetes mellitus 
tipo 2. 
5. La variación en el tiempo (~4 años) de la glucosa basal plasmática y la 
probabilidad de desarrollar diabetes mellitus tipo 2 se vieron significativamente 
aumentadas por alelo genético ponderado de riesgo. 
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6. Los sujetos que debutaron con diabetes mellitus tipo 2 presentaron tanteos 
genéticos medios más altos que los que no lo hicieron. 
7. La hipertensión arterial y el tanteo genético (por alelo genético ponderado de 
riesgo asociado a glucosa basal o a diabetes mellitus tipo 2) predijeron, de forma 
independiente, la variación en el tiempo (~4 años) de la glucosa basal plasmática 
y la probabilidad de desarrollar diabetes mellitus tipo 2. 
8. La hipertensión arterial o los tratamientos específicos antihipertensivos, y la 
variación genética común asociada a los niveles de glucosa basal y al riesgo de 
diabetes mellitus tipo 2 mediado por su acción sobre la célula beta pancreática, no 
se influyeron mutuamente en su asociación con la variación en el tiempo de la 
glucosa basal plasmática o la probabilidad de desarrollar diabetes mellitus tipo 2.  
9. Por tanto, la influencia que la hipertensión arterial o su tratamiento ejerció sobre 
la variación en el tiempo de la glucosa basal plasmática o la probabilidad de 
desarrollar diabetes mellitus tipo 2 fue homogénea independientemente de la 
susceptibilidad genética conferida por la variación genética común asociada a los 
niveles de glucosa basal o al riesgo de diabetes mellitus tipo 2.   
10. Recíprocamente, el efecto que la variación genética común asociada a los niveles 
de glucosa basal plasmática o al riesgo de diabetes mellitus tipo 2 ejerció sobre la 
variación en el tiempo de la glucosa basal plasmática o la probabilidad de 
desarrollar diabetes mellitus tipo 2 no fue mayor en la presencia de hipertensión 
arterial, de hipertensión tratada o de tratamientos específicos antihipertensivos. 
11. Los posibles factores de confusión adicional de riesgo de desarrollar diabetes 
mellitus tipo 2 (presión arterial media, índice de masa corporal, tabaquismo, 
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niveles de colesterol HDL y triglicéridos, y consumo de alcohol) no parecieron 
explicar la mayoría de las asociaciones estadísticamente significativas 
encontradas en los modelos ajustados para la edad y el sexo, con ajuste adicional 
para el valor de glucosa basal plasmática en el análisis de la variación en el 
tiempo de la glucosa basal plasmática.    
12. Este trabajo permite asomarnos a la posibilidad de analizar efectos de interacción 
entre polimorfismos individuales x categorías específicas de fármacos 
antihipertensivos en muestras poblacionales más grandes, o bien agrupando 
polimorfismos de acuerdo a las vías biológicas a través de las cuales se ha 
descrito que operan, para responder a la cuestión de si puede haber fundamento 
biológico para un peor control de la glucosa basal plasmática o un mayor  riesgo 
de desarrollar diabetes mellitus tipo 2 asociados a los tratamientos 
antihipertensivos. 
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1. BACKGROUND 
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1.A. The magnitude of the problem: The global burden of type 2 diabetes mellitus 
According to the World Health Organization (WHO), diabetes mellitus is defined 
by plasma fasting glucose levels ≥126 mg/dl (7.0 mmol/l), or by the results of a 75 g oral 
glucose tolerance test (OGTT), having settled the diabetes diagnosis cut-off point at 200 
mg/dl (11.1 mmol/l) for plasma glucose levels 2 hours after the glucose intake (1). Also 
according to the WHO, we can define “impaired fasting glucose” when fasting glucose 
levels are 110 mg/dl (6.1 mmol/l) or higher, but lower than 126 mg/dl (7 mmol/l). 
“Impaired glucose tolerance” can be diagnosed if OGTT 2-hour glucose levels are 140 
mg/dl (7.8 mmol/l) or higher, but lower than 200 mg/dl. Both impaired fasting glucose 
and impaired glucose tolerance are metabolic intermediate stages between the normal and 
the pathological state. A 2003 follow-up report from the American Diabetes Association 
(ADA) revisited the lower value of the range of plasma fasting glucose values used to 
define impaired fasting glucose: this was lowered from ≥110 (6.1 mmol/l) to ≥100 (5.6 
mmol/l), to make it more comparable with the impaired glucose tolerance test values (2) 
(Table 1). However, the WHO has not changed its threshold level. Additionally, the last 
recommendations from the ADA include hemoglobin A1C (HbA1C) value as another 
criterion for the diagnosis of diabetes mellitus, with a cut-off point of ≥6.5% (3,4).  
Table 1. Current ADA definitions for diabetes mellitus (only one criterion is needed). 
1. A1C ≥6.5% in a certified laboratory and using a standardized to the DCCT assay 
 
2. Fasting plasma glucose ≥126 mg/dl (7.0 mmol/l) 
 
3. 2-hour plasma glucose ≥200 mg/dl (11.1 mmol/l) during an oral load test with 75 g of 
anhydrous glucose dissolved in water  
 
4. A random plasma glucose ≥200 mg/dl (11.1 mmol/l) in a patient with classic 
symptoms of hyperglycemia or hyperglycemic crisis 
 
Unless unequivocal hyperglycemia, criteria 1-3 should be confirmed by repeat testing 
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Type 2 diabetes mellitus (T2DM) is characterized by chronic hyperglycemia due 
to insulin resistance of peripheral tissues (skeletal muscle, liver, adipose tissue and, 
probably, also the brain), and insufficient compensatory insulin secretion by pancreatic β-
cells (5). In contrast to insulin resistance, the decline in β-cell function is considered a 
late event (6), and has been shown to be caused, at least in part, by an irreversible loss of 
the β-cell mass (7). T2DM patients do not strictly need insulin for survival and there is no 
autoimmune destruction of the beta cells. Secondary T2DM may result as a consequence 
of different diseases, such as acromegaly, Cushing's syndrome, thyrotoxicosis, 
pheochromocytoma, chronic pancreatitis, cancer and drugs. 
The incidence and prevalence rates of T2DM are reaching alarming proportions. 
Among the adults older than 30 years old from the United States of America (USA), 
T2DM prevalence has been reported to be 13.7% for men (95% Confidence Interval (CI): 
12.0-15.4%) and 11.7% for women (95% CI: 10.4-13.0%) in the pooled 2003-2006 
National Health and Nutrition Examination Survey (NHANES) (8). Moreover, 
approximately one third of all the T2DM cases in 2003-2006 were estimated to remain 
undiagnosed. In parallel, the economic impact of T2DM is enormous, with an estimated 
health cost of 132 billion USA dollars during 2002 in the USA (9). These data support 
the notion that preventive measures contributing to ameliorate this enormous burden 
would therefore have a very favorable impact in terms of population health, resources 
utilization and financial costs.  
 In Spain, the prevalence rates of T2DM are quite similar to the data reported from 
the USA. The Spanish Insulin Resistance Study recruited 2,949 subjects aged 34-69 from 
diverse geographical sites and found a prevalence rate of 10.2% (95% CI not reported) 
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for T2DM, according to the 1,999 WHO T2DM diagnostic criteria (10). More recent 
cross-sectional studies including subjects from different regions have revealed prevalence 
rates ranged between 10% and 15%, finding higher rates in males and in older people 
(11). Several factors may be responsible for the increasing prevalence rates, namely aging 
populations, adverse environmental factors of the Occidental lifestyle (i.e., high-caloric 
diets, physical inactivity, and sedentary habits), higher obesity rates, the higher life 
expectancy for people with cardiovascular risk factors, and the increasingly higher 
incidence rates of T2DM in the population (12). The most recent epidemiological data 
from Spain point to an overall 13.8% (95% CI: 12.8-14.7%) prevalence rate of T2DM, 
and an additional 9.2% (95% CI: 8.2-10.2%) prevalence rate of abnormal glucose 
tolerance (13).  
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1.B. Hypertension: the other epidemic 
Hypertension is defined as a systolic blood pressure ≥140 mmHg or a diastolic 
blood pressure ≥90 mmHg, according to the American Heart Association (14). High 
blood pressure is a universal problem: Overall, 26.4% (95% CI: 26.0-26.8%) of the adult 
population in 2000 had hypertension (26.6% of men (95% CI: 26.0-27.2%) and 26.1% of 
women (95% CI: 25.5-26.6%)), and 29.2% (95% CI: 28.8-29.7%) overall were projected 
to have this condition by 2025 (15). The estimated total number of adults with 
hypertension in 2000 was 972 million (95% CI: 957-987 million); 333 million (95% CI: 
329-336 million) in economically developed countries and 639 million (95% CI: 625-654 
million) in economically developing countries. The number of adults with hypertension 
in 2025 was predicted to increase ~60%, up to 1.56 billion (95% CI: 1.54-1.58 billion).  
In the USA, data from the National Health and Nutrition Examination Survey 
(NHANES) 2003–2006 indicate that 33.6% of US adults older than 20 years of age have 
hypertension (16). This amounts to an estimated 74,500,000 US adults with hypertension. 
The prevalence of hypertension is nearly equal between men and women. African-
American adults have among the highest rates of hypertension in the world, at ~43%. 
Among hypertensive adults, approximately 78% are aware of their condition, 68% are 
using antihypertensive medication, and only 44% of those treated had their hypertension 
controlled. It has been reported that as many as 45 million people in the USA are 
following antihypertensive treatment (14).  
In Spain, the estimated prevalence of hypertension in the overall population is 
around 45%, with higher prevalence rates in older people, and in males than in females 
(17). Only one fourth of this population is strictly controlled.  
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1.C. The association of hypertension with hyperglycemia and type 2 diabetes 
mellitus. 
Solid evidence suggests that there is a close association between hypertension and 
incident T2DM. Longitudinal studies have shown that higher blood pressure is associated 
with increased risk of T2DM (18). Using data from the Atherosclerosis Risk In 
Communities (ARIC) Study, the Coronary Artery Risk Development in Young Adults 
(CARDIA) Study, and the Framingham Heart Study, Wei et al. reported that a higher 
blood pressure was a risk factor for new-onset T2DM in middle-aged African American 
and white persons in the community (19). In African Americans, the higher diabetes 
incidence among hypertensive individuals might be explained by body mass index 
(BMI), fasting glucose, triglyceride, and HDL cholesterol. In whites, however, pre-
hypertension and hypertension were associated with greater risk of diabetes, beyond that 
explained by other risk factors. Nonetheless, African Americans, regardless of blood 
pressure, had greater risks of developing diabetes than whites. Other additional 
longitudinal studies using prospectively followed-up cohorts have shown an association 
between blood pressure and risk of developing T2DM (20,21). 
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1.D. Dysglycemic effects of the antihypertensive drugs 
The possible influence due to antihypertensive drugs on glycemic control and 
T2DM onset has been examined in the medical literature for nearly half a century: thiazides 
(22,23) and beta-blockers (24,25) have long been considered to be associated with T2DM 
onset and deleterious effects upon glycemic control. Other diuretics have not been definitely 
implicated in T2DM onset in the medical literature. Renin-angiotensin system agents 
(angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB)) 
have been reported to have protective effects in this regard. 
1.D.1. Hyperglycemic effects of thiazides 
Thiazides deliver a high sodium load in the distal convoluted tubule, with a 
resulting increase in potassium excretion. Moreover, they activate the renin-angiotensin 
system (RAS) through volume depletion, which in turn leads to increased aldosterone 
secretion and further enhanced potassium excretion (26). One of the hypotheses that 
could explain the risk of T2DM associated with thiazides use is that the diuretic-induced 
hypokalemia leads to a higher secretion ratio of proinsulin to insulin -biologically less 
active than insulin-, which might impair glucose homeostasis. This idea has been 
reinforced by recent reports of the association between serum and dietary potassium and 
the risk of incident T2DM (27). 
Nevertheless, the exact reason why thiazides confer a higher risk of T2DM 
remains to be proven: whereas recent studies have failed to show a direct association 
among changes in potassium levels during diuretic treatment with new-onset T2DM (28), 
other authors continue to suggest the possibility of preventing new-onset T2DM due to 
thiazides through potassium supplementation (29). However, additional factors have been 
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proposed as causal mechanisms: hypomagnesaemia (30), direct pancreatic beta cell 
damage due to free fatty acids (31), visceral fat redistribution, liver fat accumulation, 
low-grade inflammation, and aggravated insulin resistance (32). Adipose tissue gene 
expression of serum amyloid A and serum levels of E selectin were higher after 
hydrochlorothiazide treatment compared to candesartan (33), what suggests that 
additional factors may be operating.  
Most old epidemiological studies and recent empowered clinical trials and meta-
analyses (34-36) support an association between thiazides and risk of incident T2DM. 
Nonetheless, previous work had failed to demonstrate a significant association (37-39). 
Disparities in the results may be due to: differences in the particular design of every study 
(intention-to-treat analyses vs. actual on-therapy; randomized clinical trial vs. 
observational; primary aim vs. post-hoc analyses); differences among population samples 
(i.e., whole population vs. only the elderly); lack of statistical power; failure to 
appropriately adjust for confounders (blood pressure, drug doses or body mass index 
(BMI) (40)); and use of different criteria for diagnosing T2DM. At last, the percentage of 
the variability of glucose levels as a response to thiazides explained by ethnicity has been 
estimated to be about 13% (41), which means that genetic factors should also be 
accounted for.  
Twenty-five years ago, Wilson et al. highlighted the higher risk of incident T2DM 
associated with thiazides treatment in the Framingham Heart Study (23): thiazides use 
was significantly associated with T2DM onset in the univariate analysis (P<0.001). The 
association still remained significant for women in the multivariate regression model 
(P<0.01), but that was not the case for men. In the “Health Professionals Follow-up 
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Study”, another different longitudinal prospectively follow-up cohort study, Taylor et al. 
showed that the risk of developing T2DM was higher for subjects who received thiazides 
for hypertension than for subjects who received no thiazides, in fully-adjusted 
multivariate regression models (20%, 45% and 36% higher for old women, young women 
and men, respectively) (35).  
Some criticism has been brought against data from longitudinal follow-up cohort 
studies, in which the possibility of allocation bias or confounding by indication is a major 
concern (42). As additional randomized clinical trials and meta-analyses that include data 
exclusively from randomized clinical trials have been published, further evidence 
supports an association between thiazides and risk of T2DM. As an example, the 
“Intervention as a Goal in Hypertension Trial” (INSIGHT) found fewer cases of new 
onset T2DM with nifedipine compared to the potassium-sparing/thiazide combination 
coamilozide (4.3% vs. 5.6%, respectively; P=0.023) (43).  
The widespread use of meta-analyses has also overcome the limitation of low 
statistical power, which has traditionally precluded from drawing definitive conclusions. 
This limitation was an issue in the “Systolic Hypertension in the Elderly Program Trial” 
(SHEP), where the difference in new-onset T2DM incidence among those subjects 
treated with chlorthalidone vs. placebo did not reach statistical significance (8.6% vs. 
7.5%; hazard ratio (HR): 1.2; 95% confidence interval (CI): 0.9-1.5; P=0.25) (39).  
Contrarily, as cited above, in a post hoc subgroup analyses from the 
“Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial” 
(ALLHAT) among non-diabetic participants who were randomized to receive treatment 
with chlorthalidone (n=8,419), amlodipine (n=4,958), or lisinopril (n=5,034), and who 
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were observed for a mean 4.9-year period, the odds ratios (ORs) of developing T2DM at 
2 years with lisinopril (OR=0.55; 95% CI: 0.43-0.70) or amlodipine (OR=0.73; 95% CI: 
0.58-0.91) vs. chlorthalidone were significantly lower than 1.0 (P<0.001 and P=0.006, 
respectively) (34).  
 Furthermore, in a network meta-analysis of 22 randomized clinical trials 
involving 143,153 participants, Elliot et al. reported a statistically significant 23% (95% 
CI: 6-37%) higher risk of T2DM onset in hypertensive subjects treated with thiazides as 
compared to placebo (P=0.009) (Figure 1) (36).  
 
Figure 1: Odds ratios (ORs) for new-onset T2DM after anti-hypertensive drug exposures 
according to Elliot et al. (36).  
 
 
 
 
Figure 1 is comparing each anti-hypertensive exposure group with diuretics as a reference group 
(OR=1). Diuretics, but not beta-blockers, pose a higher risk than placebo or ACEI/ARB. Taken 
from Elliot et al. (with permission). 
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1.D.2. Hyperglycemic effects of beta-blockers 
In regard to beta-blockers, whereas a few studies did not support an association 
between beta-blockers therapy for hypertension and T2DM onset (44), most of the 
classical, non-randomized older studies did (24,25). Gress et al., for instance, reported a 
28% excess risk for T2DM onset in hypertensive subjects treated with beta-blockers in 
the longitudinal ARIC Study (“Atherosclerosis Risk In Communities”) in multi-adjusted 
regression models (37). Again, in an attempt to avoid the issue of confounding by 
indication, randomized clinical trials and meta-analyses of the randomized clinical trials 
that evaluated beta-blockers use in hypertensive patients have been carried out. One 
example is the one conducted by Bangalore et al., which showed a 22% (95% CI: 12%-
33%) excess risk of T2DM onset with the use of beta-blockers for hypertension as 
compared to calcium channel blockers (CCB) or angiotensin converting enzyme (ACE) 
inhibitors (p<0.0001) (Figure 2) (45). In addition, some recent randomized clinical trials 
and meta-analyses report a higher risk of T2DM onset when the combination of diuretics 
and beta-blockers is used to treat hypertension, such as the study by Gupta et al. (46), 
which showed that use of atenolol, either alone or along with a diuretic, was one of the 
major determinants of new onset T2DM in hypertensive patients. Another meta-analysis 
published by Mason et al., which included 76,949 treated individuals, reported a higher 
risk of new-onset T2DM for the combined use of old beta-blockers and thiazides (RR: 
1.23; 95% CI: 1.16-1.30) (47).  
Plausible mechanisms that could explain the contribution of beta-blockers to the 
development of T2DM include weight gain, attenuation of the beta-receptor–mediated 
release of insulin from pancreatic beta cells, decreased insulin sensitivity, changes in the 
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level of aerobic exercise or subtle changes in the cellular actions of insulin (48). Intra-
class variation, or different incidence rates of T2DM with the use of different 
formulations of beta-blockers, has been reported, with higher T2DM incident rates for old 
drugs and metoprolol than for carvedilol (49). 
 
Figure 2: Risk ratios for new-onset T2DM in randomized clinical trials comparing beta-
blockers vs. other anti-hypertensive therapies, after excluding diuretics , as reported by 
Bangalore et al. (44).  
 
 
In Figure 2 it is shown that most studies report a higher T2DM risk for beta-blockers than for ACE 
inhibitors or CCB. Taken from Bangalore et al. (with permission). 
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1.D.3. Protective glycemic effects of angiotensin converting enzyme inhibitors 
and the angiotensin receptor blockers 
On the other hand, ACE inhibitors and ARB have been proposed to have a 
protective effect in regard to T2DM onset and glycemic control (37), beyond the neutral 
effects attributed to calcium channel blockers (51). The first study to report a lower 
incidence of new-onset T2DM with the use of for treating hypertension with ACE 
inhibitors was the CAPPP (“Captopril Prevention Project”) (52), which evaluated the 
effects of captopril versus conventional antihypertensive therapy in patients with diastolic 
hypertension. The relative risk (RR) for T2DM onset associated with use of captopril was 
0.86 (95%CI: 0.74-0.99), as compared to conventional treatment, which included beta-
blockers and diuretics (P=0.04).  
In the HOPE (“Heart Outcomes Prevention Evaluation”) study, the hypertensive 
subjects treated with ramipril showed a lower risk of in new-onset T2DM in secondary 
analyses (RR: 0.66; 95% CI: 0.52-0.84; P<0.001) (53). Similar results were observed in 
the ANBP-2 (“Australian National Blood Pressure-2”) survey: the relative risk (RR) for 
new-onset T2DM in the ACE inhibitor-treated versus the diuretic-treated group was 0.69 
(95% CI: 0.56-0.85; P<0.001) (54).  
In the VALUE (“Valsartan Anti-hypertensive Long-term Use Evaluation) study, 
the RR for T2DM onset was 0.81 (95% CI: 0.74-0.83) in patients treated with valsartan 
compared to patients treated with amlodipine (55). The results of the VALUE and 
ALLHAT (34) studies directly comparing use of ARB with CCB, which are thought to be 
metabolically neutral, suggest a true beneficial effect of ARB on T2DM development. 
This effect seems to be directly related to the blockade of the biological effects of 
46 
 
angiotensin II beyond the “relative” benefit exclusively driven by comparing them with 
drugs with deleterious effects in regard to risk of T2DM onset, such as thiazides or beta-
blockers.  
The LIFE (“Losartan Intervention For Endpoint reduction”) study was a double-
blind, randomized, parallel-group trial to compare the effects of losartan and atenolol on 
cardiovascular morbidity and mortality in 9,193 high-risk hypertensive patients (systolic 
BP: 160-200 mmHg; or diastolic BP: 95-115 mmHg), with left ventricular hypertrophy. 
This study provided further evidence that new-onset T2DM was less frequent (RR: 0.75; 
95% CI: 0.64-0.89; P<0.001), and insulin-sensitivity was higher with losartan than with 
atenolol (56).  
In the CHARM (“Candesartan in Heart failure Assessment of Reduction in 
Mortality and morbidity”) study, patients with chronic heart failure were randomly 
assigned to receive candesartan or placebo in addition to standard anti-heart failure 
therapy (57). Significantly fewer patients in the candesartan-treated group developed 
new-onset T2DM compared to the placebo group (RR: 0.81; 95% CI: 0.66-0.99; P=0.02). 
Notwithstanding the previous result, a recent paper has shown no evidence that the 
addition of the ARB telmisartan to usual care prevents incident T2DM or leads to 
regression of impaired fasting glucose or impaired glucose tolerance in people at high 
risk for cardiovascular disease but free from diabetes (58). 
Combining several individual studies, in a meta-analysis including more than 
103,000 patients, Burke et al. found a significant 27% (95% CI: 7-51%) higher risk for 
calcium channel blockers and a 47% (95% CI: 12-95%) higher risk for “other 
hypertensive treatments” of developing T2DM than for subjects treated with ACE 
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inhibitors alone (P=0.007 and P=0.006, respectively) (59). Jandeleit-Dahm et al. 
performed another meta-analysis including data from randomized clinical trials including 
more than 65,000 individuals evaluating the incidence of T2DM in subjects with renin-
angiotensin axis blockade vs. non-blockade, finding an overall risk ratio = 0.78 (95% CI: 
0.74-0.83) of T2DM onset for subjects with axis blockage (Figure 3) (60). Similar results 
have been reported by Gillespie et al. (61).  
 
 
Figure 3: Risk ratios for new-onset T2DM in comparative outcome trials involving the use of 
renin-angiotensin axis blockade vs. non-blockade, as reported by Jandeleit-Dahm et al. (60).  
 
 
Figure 3 shows a lower risk of incident T2DM with the use of ACE inhibitors/ARB. Taken from 
Jandeleit-Dahm et al. (with permission). 
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More recently, the results from the NAVIGATOR (“Nateglinide And Valsartan in 
Impaired Glucose Tolerance Outcomes Research”) study have been published (62). This 
study is a double-blind, randomized clinical trial with a 2-by-2 factorial design including 
9,306 patients with impaired glucose tolerance and established cardiovascular disease or 
cardiovascular risk factors. The intervention consisted of the administration of valsartan (up 
to 160 mg daily) or placebo, in addition to lifestyle modification, with a five-year follow up. 
The cumulative incidence of T2DM was 33.1% in the valsartan group, as compared with 
36.8% in the control group (HR=0.86; 95% CI: 0.80-0.92; P<0.001). Valsartan treatment 
increased glucose-stimulated insulin release and insulin sensitivity in normotensive subjects 
with impaired glucose metabolism in a recent report by van der Zijl et al. (63).  
The way ACE inhibitors and ARB reduce the risk of T2DM remains uncertain, 
though several mechanisms, such as decreased renal potassium wasting, and improved islet 
blood flow and pancreatic beta cell perfusion by reducing angiotensin II-mediated 
vasoconstriction in the pancreas, have been proposed (60).   
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1.E. Genetic contribution to the risk of T2DM  
T2DM is a multi-factorial disease. Genetic background is partially responsible for 
T2DM risk. This has long been thought, as some T2DM patients have normal weight, and 
reciprocally, many obese subjects never develop T2DM, what suggests that T2DM is not 
exclusively caused by environmental factors. Moreover, certain ethnic minorities do 
show high T2DM prevalence (up to 21% in Pima Indians) (64). Also, T2DM clusters in 
families: first-degree relatives have, compared with the general population, more than 3-
fold higher risk of developing the disease (65). It has also been reported a higher 
concordance for T2DM in monozygotic compared with dizygotic twins (≈70% vs. 10%) 
(66).  
T2DM is considered to be polygenic, since it does not follow a Mendelian pattern 
of transmission. It follows a “complex pattern of genetic transmission”, caused by the 
simultaneous occurrence of common (minor allele frequencies >5%) DNA sequence 
variations in many genes (67). The sum of the individual modest effects of all the 
intervening genes confers an increased susceptibility toward adverse environmental 
factors. Single nucleotide polymorphisms (SNPs), exchanges of single base pairs, cover 
approximately 90% of the sequence variation within the human genome (68), and are 
regarded as the major determinants of the individual predisposition to complex diseases. 
Thus, the term “genetic polymorphism” defines monogenic traits that exist in the normal 
population in at least two phenotypes, neither of which is rare (69).  
There has been a huge international effort for the identification of the genetic 
predisposition to T2DM. Two main approaches have been followed to achieve this aim: 
candidate gene studies and the hypothesis-free genome-wide association scan approach 
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(GWAS). With the former, candidate genes are combed through for common genetic 
variants, and these variants’ allele frequencies are finally analyzed for being altered in 
T2DM cases compared with healthy controls. Candidate genes are identified from 
different sources: 1. Basic research of cell and mouse studies, which was the case for 
PPARg (on chromosome 3p25) (70) and KCNJ11 (on chromosome 11p15.1) (71,72); 2. 
Genetics of rare monogenic forms of human diabetes, whose causal genes’ mutations are 
known to exert strong effects and cause monogenic forms of diabetes (maturity onset 
diabetes of the young (MODY), Wolfram syndrome, etc.); this was the case for HNF1B 
(chromosome 17q12) (73) and WFS1 (chromosome 4p16.1) (74); and 3. Human family 
linkage studies, such as diabetes-associated variants in TCF7L2 (chromosome 10q25.3) 
(75,76).  
The most recent and successful approach to identify novel risk alleles or replicate 
those previously reported to be associated with T2DM is the systematic genotyping of 
several hundred thousand SNPs in tens of thousands of cases and controls using high-
density SNP arrays (GWAS), through a technology that has become widespread and 
affordable in recent times. In these GWAS, the frequency of all these genotyped SNPs is 
then compared between cases and controls, and alleles significantly more frequent in 
cases than in controls (at an arbitrarily established level of genome-wide statistical 
significance to correct for multiple testing) are considered risk alleles. In early 2007, 
Sladek et al. (77) were the first, not only to confirm TCF7L2 as a T2DM risk genetic 
locus, but also to identify additional novel T2DM risk loci, namely SLC30A8 
(chromosome 8q24.11) and HHEX (chromosome 10q23.33). Next, FTO (chromosome 
16q12.2) was characterized as a T2DM risk gene through its action upon obesity (78,79).  
51 
 
The aforementioned associations for HHEX, SLC30A8, TCF7L2, FTO, KCNJ11, 
and PPARG were replicated in large GWAS, which also revealed three novel T2DM risk 
loci: CDKAL1 (chromosome 6p22.2), IGF2BP2 (chromosome 3q27.2) and a genomic 
region between CDKN2A and CDKN2B on chromosome 9p21 (80-83). In 2008, a meta-
analysis of GWAS comprising approximately 60,000 subjects reported six additional risk 
loci: JAZF1 (chromosome 7p15.2-p15.1), THADA (chromosome 2p21), ADAMTS9 
(chromosome 3p14.1), NOTCH2 (chromosome 1p13-p11), and two inter-genic regions, 
one between CDC123 and CAMK1D on chromosome 10p13 and another between 
TSPAN8 and LGR5 on chromosome 12q21-q22 (84). All the common variants had low 
effect sizes ORs for T2DM risk (in the range 1.09-1.13). In this study, DCD, on 
chromosome 12q13.1, approached genome-wide statistical significance and VEGFA, on 
chromosome 6p12, which had shown a significant signal in a previous GWAS (81), did 
too.   
More recently, confirmed diabetes risk alleles of KCNQ1 on chromosome 
11p15.5 were reported in Asian GWAS that also included European replication cohorts 
(85). Moreover, a meta-analysis of 13 GWAS (>83,000 subjects) revealed common 
variation in the MTNR1B gene on chromosome 11q21-q22 that conferred an increased 
risk for T2DM (86), and this was verified in subsequently published studies (87). 
Additionally, Rung et al. reported that a genetic variant near KIAA1486/IRS1, on 
chromosome 2q36, was associated with T2DM, insulin resistance and hyper-insulinemia 
(88). 
After that, two additional GWAS have enlarged the list of T2DM associated 
SNPs: in the first one, Dupuis et al., using data from MAGIC (“Meta-Analyses of 
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Glucose and Insulin-related traits Consortium”), identified additional common variants 
associated with fasting glucose levels (see below, section 1.F). In their study, they also 
tested these loci for association with incident T2DM as a dichotomous trait in up to 
40,655 cases and 87,022 non-diabetic controls, demonstrating that the fasting glucose-
raising alleles at 7 loci (in or near ADCY5 (chromosome 3q21.1), PROX1 (chromosome 
1q32.2-q32.3), GCK (chromosome 7p15.3-p15.1), GCKR (chromosome 2p23) and 
DGKB-TMEM195 (chromosome 7p21.2), and the known T2DM genes TCF7L2 and 
SLC30A8 were robustly associated (P<5×10−8) with increased risk of T2DM (89).  
In the other study, Voight et al., for the DIAGRAM + (“Diabetes Genetics 
Replication And Meta-analysis”) Consortium, combined genome-wide association data 
from 8,130 T2DM cases and 38,987 controls of European descent and followed up novel 
meta-analysis signals in a sample including 34,412 cases and 59,925 controls, identifying 
12 novel T2D-association signals with combined P<5x10-8 (90). These included a second 
independent signal at the KCNQ1 locus, the first report of a X-chromosomal association 
(near DUSP9), and a further instance of overlap between loci implicated in monogenic 
and multifactorial forms of diabetes (HNF1A). The two signals at KCNQ1 were in low 
linkage disequilibrium (LD), which is defined as the non-random association of alleles of 
SNPs that reside one close to another. The remaining SNPs are in or near the following 
loci: HMGA2 (chromosome 12q15), CENTD2 (chromosome 11q13.4), KLF14 
(chromosome 7q32.2), PRC1 (chromosome 15q26.1), TP53INP1 (chromosome 8q22), 
ZBED3 (chromosome 5q14.1), ZFAND6 (chromosome 15q25.1), BCL11A (chromosome 
2p16.1) and CHCHD9 (chromosome 9q21.31). Two more SNPs have recently been 
reported to be associated with T2DM: in or near HCCA2, on chromosome 11p15.5 (91) 
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and in or near RBMS1/ITGB6, on chromosome 2q24.2 (92). These genetic research 
efforts of the last decade have led to the identification of around 41 T2DM-associated 
susceptibility loci as of June 2009, comprising 40 autosomal loci and 1 locus in the 
sexual X chromosome (Table 2). At last, a very recent report suggests that there may be 
another signal showing genome-wide statistical significance at the vicinity of 
GATAD2A/CILP2/PBX4, to be further replicated (93).  
Remarkably, most of the aforementioned SNPs are tagging genetic loci known to 
influence pancreatic beta cell function. A summary of the different biologic pathways 
that these beta cell genetic loci may be related to is shown in Table 3. Proposed 
mechanisms per loci discovered in recent GWAS that influence beta cell function include 
beta-cell development, insulin maturation, glucose transport, and insulin secretion (i.e., 
incretin-mediated secretion) or release (i.e., through the activation of the potassium 
channel). For this study, we decided not to exclude those loci for which an effect on 
insulin secretion could not be definitely ruled out owing to the fact that they regulate 
molecular pathways that may be indirectly related to beta-cell function, such as signal 
transduction, zinc finger protein regulation, mitogenic activity and others. However, for 
six of the T2DM-SNPs, in or near IRS1, PPARγ, ADAMTS9, KLF14, HMGA2 and FTO, 
mechanisms other than those related to the beta cell function have been proposed 
(namely, insulin-resistance as opposed to beta cell function) (90,94). We therefore 
excluded these SNPs that had been suggested to modify T2DM risk through insulin 
action (as opposed to insulin secretion), or through other well-defined non beta-cell 
mechanisms (namely, obesity in case of FTO). We also removed from the dataset SNP 
rs2237892, at KCNQ1, associated with T2DM risk mostly in Asian populations. In 
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addition, no genotyped or imputed data were available in Framingham for rs1800574, at 
TCF1/HNF1A, or for DUSP9, in chromosome X. Thus, we finally used an updated list -
by September 2010- of 33 SNPs that reportedly influence beta cell function for the 
T2DM analyses.  
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Table 2. Common genetic variation in autosomal genetic loci associated with T2DM in published 
GWAS.  
SNP Genetic locus Chromosome Risk allele Beta cell SNP GWAS (citation) 
rs10923931 NOTCH2 1 T Yes Zeggini (84) 
rs340874 PROX1 1 C Yes Dupuis (89) 
rs780094 GCKR 2 C Yes Dupuis (89) 
rs7578597 THADA 2 T Yes Zeggini (84) 
rs243021 BCL11A 2 A Yes Voight (90) 
rs7593730 RBMS1/ITGB6 2 C Possibly Qi (92) 
rs7578326 KIAA1486/IRS1 2 A No Rung (88) 
rs1801282 PPARg 3 C No Saxena (80) 
rs4607103 ADAMTS9 3 C No Zeggini (84) 
rs11708067 ADCY5 3 A Yes Dupuis (89) 
rs1470579 IGF2BP2 3 C Yes Saxena (80) 
rs10010131 WFS1 4 G Yes Sandhu (74) 
rs4457053 ZBED3 5 G Yes Voight (90) 
rs7754840 CDKAL1 6 C Yes Saxena (80) 
rs9472138 VEGFA 6 T Possibly Zeggini (84) 
rs2191349 DGKB/TME195 7 T Yes Dupuis (89) 
rs864745 JAZF1 7 T Yes Zeggini (84) 
rs4607517 GCK 7 A Yes Dupuis (89) 
rs972283 KLF14 7 G No Voight (90) 
rs896854 TP53INP1 8 T Yes Voight (90) 
rs13266634 SLC30A8 8 C Yes Saxena (80) 
rs10811661 CDKNA/2B 9 T Yes Saxena (80) 
rs13292136 TLE4/CHCHD9 9 C Yes Voight (90) 
rs12779790 CDC123,CAMK1D 10 G Yes Zeggini (84) 
rs1111875 HHEX 10 C Yes Saxena (80) 
rs7903146 TCF7L2 10 T Yes Grant (75) 
rs2334499 HCCA2 11 T Possibly Kong (91) 
rs231362 KCNQ1 11 G Yes Voight (90) 
rs2237892 KCNQ1 11 C Yes Unoki (85) 
rs5215 KCNJ11 11 C Yes Saxena (80) 
rs1552224 CENTD2 11 A Yes Voight (90) 
rs10830963 MTNR1B 11 G Yes Prokopenko (86) 
rs1153188 DCD 12 A Possibly Zeggini (84) 
rs1531343 HMGA2 12 C No Voight (90) 
rs7961581 TSPAN8,LGR5 12 C Yes Zeggini (84) 
rs7957197 OASL/TCF1(HNF1A) 12 T Yes Voight (90) 
rs11634397 ZFAND6 15 G Yes Voight (90) 
rs8042680 PRC1 15 A Yes Voight (90) 
rs9939609 FTO 16 A No Van Hoeck (78) 
rs757210 HNF1B/TCF2 17 T Yes Winckler (73) 
SNP: single nucleotide polymorphism. GWAS: genome-wide association scan. 
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Table 3. Proposed patho-physiological mechanisms that could explain impairment of beta cell 
function mediated by common genetic variation (95).  
 
SNP Chr Nearest gene  Biologic pathways Generic function 
rs10923931 1 NOTCH2 Pancreatic organogenesis. Cell growth Beta cell development 
rs340874 1 PROX1 Encodes HNK4, necessary for beta cell development Beta cell development 
rs7578597 2 THADA Apoptosis. Transport activity. Not well known Diverse/unknown 
rs243021 2 BCL11A HbF levels. Beta cell differentiation Beta cell development 
rs780094 2 GCKR Inhibits glucokinase in beta cell. MODY Insulin secretion, not incretins 
rs7593730 2 RBMS1/ITGB6 RNA processing/integration; inflammation, emphysema Diverse/unknown 
rs11708067 3 ADCY5 Adenylate cyclase. GLP1, AMPc and insulin secretion Incretins. Insulin secretion 
rs1470579 3 IGF2BP2 Pancreatic development. Morphogenesis. Protein binding Beta cell development 
rs10010131 4 WFS1 GLP1-induced insulin secretion Incretins. Insulin secretion 
rs4457053 5 ZBED3 Encodes Zn finger. Unknown Diverse/unknown 
rs7754840 6 CDKAL1 Signal transducer. Down regulates insulin expression Diverse/unknown 
rs9472138 6 VEGFA Vascular endothelial growth factor. Angiogenesis. Unknown Diverse/unknown 
rs864745 7 JAZF1 Zn finger protein. Encodes a nuclear receptor Diverse/unknown 
rs2191349 7 DGKB/TMEM195 Protein kinase and insulin secretion Insulin secretion, not incretins 
rs4607517 7 GCK Phosphorilates glucose through glycolysis. MODY Diverse/unknown 
rs13266634 8 SLC30A8 Zn transporter for insulin maturation Insulin maturation 
rs896854 8 TP53INP1 Tumor protein p53 Diverse/unknown 
rs10811661 9 CDKNA/2B Pancreatic regenerative capacity Beta cell development 
rs13292136 9 TLE4/CHCHD9 Transcription regulator. Unknown Diverse/unknown 
rs1111875 10 HHEX Pancreatic organogenesis. Insulin secretion (glucose mediated) Insulin secretion, not incretins 
rs12779790 10 CDC123, CAMK1D Cell division cycle (CDC123)/calmodulin protein kinase ID Insulin secretion, not incretins 
rs7903146 10 TCF7L2 Response to incretins. Chromatin integrity. Signal transduction  Incretins. Insulin secretion 
rs5215 11 KCNJ11 Potassium channel. Insulin release. Glucagon secretion Glucose transport 
rs1552224 11 CENTD2 Regulates movement of actine filaments in cell cycle Diverse/unknown 
*rs2237892 11 KCNQ1 Potassium channel. Insulin release Glucose transport 
rs231362 11 KCNQ1 Potassium channel. Insulin release Glucose transport 
rs10830963 11 MTNR1B Melatonin, circadian rhythm Diverse/unknown 
rs2334499 11 HCCA2 Protein interactor, Zn binder, liver neoplasm Diverse/unknown 
rs1153188 12 DCD Defense against bacteria. Unknown Diverse/unknown 
rs7961581 12 TSPAN8,LGR5 Protein glycosilation and signal transducer activity. Neoplasms Diverse/unknown 
rs7957197 12 OASL/TCF1/HNF1A Transport activity, apoptosis. Neoplasms Diverse/unknown 
rs8042680 15 PRC1 Regulate cytokinesis. Associated to tumors Diverse/unknown 
rs11634397 15 ZFAND6 Zn finger. Unknown Diverse/unknown 
rs757210 17 HNF1B/TCF2 MODY. Transcription regulator. Neoplasms Diverse/unknown 
 
SNP: single nucleotide polymorphism. Chr: chromosome. MODY: maturity -onset diabetes of the young. 
GLP-1: glucagon-like peptide 1.* rs2237892, at KCNQ1, was not included in the dataset. 
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1.F. Genetic contribution to plasma fasting glucose level regulation 
The study by Prokopenko et al. (86) also tested the association of one variant at 
MTNR1B with plasma fasting glucose as a quantitative trait. It might seem intuitive that 
those SNPs associated with T2DM would also be associated with fasting glucose, but it 
has been shown that this is not necessarily true: a large effect size on T2DM does not 
always translate into an equivalently large fasting glucose effect in non-diabetic subjects. 
For instance, the risk allele at TCF7L2, the genetic locus with the largest effect on 
T2DM, has a small effect on fasting glucose levels. Additionally, not every locus 
associated with fasting glucose within the ‘physiological’ range needs to be associated 
with ‘pathological’ fasting glucose levels and T2DM risk. We can then conclude that 
variation in fasting glucose levels in healthy individuals is not necessarily an endo-
phenotype for T2DM (89).  
It was precisely the “MAGIC” GWAS which shed light on the association 
between common genetic variation across the human genome and fasting glucose levels 
(89). In this study, variants in or near ADCY5, MADD (chromosome 11p11.2), ADRA2A 
(chromosome 10q24-q26), CRY2 (chromosome 11p11.2), FADS1 (chromosome 11q12.2-
q13), GLIS3 (chromosome 9p24.2), SLC2A2 (chromosome 3q26.1-q26.2), PROX1 and 
C2CD4B (chromosome 15) showed a genome-wide level significant association with 
fasting glucose levels, and one SNP near IGF1 (chromosome 12q22-q23), an association 
with fasting insulin and HOMA-IR (homeostasis model assessment of insulin resistance). 
Also, it confirmed the previously known associations between variants in GCK, GCKR, 
G6PC2 (chromosome 2q24.3) and MTNR1B with fasting glucose levels, and showed 
genome-wide statistical significance for the association between fasting glucose levels 
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and the recently reported DGKB-TMEM195 locus, and the T2DM-associated loci at 
TCF7L2 and SLC30A8. All these fasting glucose-associated variants seem to act by 
influencing beta cell function, including C2CD4B (96). To complete the overall view of 
glycemic traits-associated common SNPs, Saxena et al. performed a meta-analysis of 
nine genome-wide association studies (n=15,234 non-diabetic individuals) and a follow-
up of 29 independent loci (n=6,958-30,620), and identified variants at GIPR 
(chromosome 19q13.3), ADCY5, VPS13C (chromosome 15q22.2), GCKR and TCF7L2 to 
be associated with results from a 2-h oral glucose tolerance test (OGTT) (97) (Table 4). 
For the change in fasting glucose analyses, we used the full 16-fasting glucose SNPs list 
as reported by Dupuis et al. (89) (Table 4, in bold).  
Table 4. Genetic loci associated with T2DM-related quantitative traits in published GWAS .  
SNP Chr Nearest gene Trait T2DM loci Risk allele Beta cell Citation 
rs340874 1 PROX1 FG Yes C Yes Dupuis J. Nat Genet 2010. MAGIC 
rs560887 2 G6PC2 FG No C Yes Dupuis J. Nat Genet 2010. MAGIC 
rs11708067 3 ADCY5 FG Yes A Yes Dupuis J. Nat Genet 2010. MAGIC 
rs11920090 3 SLC2A2 FG No T  Yes Dupuis J. Nat Genet 2010. MAGIC 
rs2191349 7 DGKB/TMEM195 FG Yes T  Yes Dupuis J. Nat Genet 2010. MAGIC 
rs4607517 7 GCK FG Yes A Yes Dupuis J. Nat Genet 2010. MAGIC 
rs13266634 8 SLC30A8 FG Yes C Yes Dupuis J. Nat Genet 2010. MAGIC 
rs7034200 9 GLIS3 FG No A Yes Dupuis J. Nat Genet 2010. MAGIC 
rs10885122 10 ADRA2A FG No G Yes Dupuis J. Nat Genet 2010. MAGIC 
rs7903146 10 TCF7L2 FG Yes T  Yes Dupuis J. Nat Genet 2010. MAGIC 
rs11605924 11 CRY2 FG No A Possibly Dupuis J. Nat Genet 2010. MAGIC 
rs174550 11 FADS1 FG No T  Yes Dupuis J. Nat Genet 2010. MAGIC 
rs7944584 11 MADD FG No A Yes Dupuis J. Nat Genet 2010. MAGIC 
rs10830963 11 MTNR1B FG Yes G Yes Dupuis J. Nat Genet 2010. MAGIC 
rs11071657 15 FAM148B(C2CD4B) FG No A Possibly Dupuis J. Nat Genet 2010. MAGIC 
rs780094 2 GCKR FG, FI Yes C Yes Dupuis J. Nat Genet 2010. MAGIC 
rs35767 12 IGF1 FI No G No Dupuis J. Nat Genet 2010. MAGIC 
rs17271305 15 VPS13C 2hrG only No G Possibly Saxena R. Nat Genet 2010. MAGIC 
rs10423928 19 GIPR 2hrG only No A Yes Saxena R. Nat Genet 2010. MAGIC 
Chr: chromosome. FG: fasting glucose. FI: fasting insulin. 2hrG only: association only with two-hour 
glucose levels after an oral glucose tolerance test (OGTT). In bold, the 16 fasting glucose-associated SNPs. 
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1.G. Gene-hypertension and gene-drug interaction and risk of incident T2DM 
1.G.1. The concept of gene-environment interaction 
It is important to note that, in different contexts, statisticians, biologists, clinicians 
and geneticists can mean somewhat different things when they refer to “interaction”. 
Sometimes, “gene-environment interaction” is used in a very loose sense, meaning some 
sort of interplay between genetic and environmental factors. It does not necessarily 
convey a specific mode of joint action, or even a precise relationship between statistical 
risks. Other times, it is even used to express that several factors are contributing to 
disease risk, without excluding the possibility of complete independence among them. In 
these cases, using the term ‘joint action’ instead of “interaction” would be preferable 
(98). 
We define “biological interaction” as the joint effect of two factors that act 
together in a direct physical or chemical reaction; it summarizes the co-participation of 
two or more factors in the same causal mechanism of disease development (99). 
However, the term “statistical interaction” should be reserved for those cases where some 
heterogeneity of effects is present, that is, a departure from additivity of effects on a 
specific outcome scale (100). We could rather take a multiplicative model as the null 
hypothesis; that is, the relative risk of disease in individuals with both the genetic and 
environmental risk factors is the product of the relative risks of each separately. 
Therefore, any joint effect that differs from these predictions can be viewed as a 
“statistical interaction”, and as a matter of fact, the multiplicative model of departure as 
the null hypothesis is also commonly evaluated in Epidemiology (101).  
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If only one factor is present, we would call “main effect” its eventual effect on the 
risk of disease. In case two or more risk factors are present, the “marginal effect” of a risk 
factor would then be its average effect across all levels of the other risk factors. The risk 
factors are said to “interact” if the effect of one risk factor depends on the level of the 
other risk factor. The joint effect of two risk factors would then refer to both their 
marginal effects and their interaction effect. So, this joint effect between a gene and an 
environmental factor that cannot be readily explained by their separate marginal effects is 
what we will call gene-environment interaction (101). The joint effect can vary from less 
than additive (“sub-additive”) to more than multiplicative (“supra-multiplicative”) of the 
individual marginal effects. The visual representation of the presence of statistical 
interaction between the presence of 0, 1 or 2 risk alleles at a genetic locus and a drug 
exposure for determining a hypothetical level of a quantitative trait (i.e., plasma fasting 
glucose) is shown in Figure 4.  
It has been reported that the detection of an interaction effect requires a sample size 
at least four times larger than that one required for the detection of a main effect of 
comparable magnitude. However, a range of interaction effect sizes can be detected in a 
GWAS by testing for interaction or a genetic effect in an environmental subgroup, even 
when the marginal effects are not detectable (101). 
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Figure 4: Visual representation of a hypothetical statistical gene-environment  interaction effect. 
 
 
Note: Even if a main effect would be present, the three lines would be in parallel if a statistical interaction 
effect was not present. Original representation. 
  
We must make a distinction between “interaction” and “confounding” among 
environment and genetic factors. “Confounding” refers to a mixing of extraneous effects 
with the effect of interest, in such a way that an undetected correlation between the 
genetic and the environmental risk factors actually accounts for the effect, giving the 
appearance of an interaction effect; this can happen in populations with latent 
stratification, or when genes influence on behaviors that modify the incidence of some 
diseases. Yet, for most situations, this will not be a matter of concern, as genotype and 
environmental risk factors are usually independent and genetic background is not 
influenced by the environment (concept of “Mendelian randomization”) (102).  
  It has been proposed that the relevant research questions that could be addressed 
by a gene-environment interaction study, beyond simply analyzing the main gene effects, 
include (97,103):  
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a. The clinical relevance of a gene-environment interaction, where the 
interaction itself is of interest; the aim of an initial study is primarily 
hypothesis-generating (exploratory), yet in other cases it will be 
hypothesis-testing (confirmatory); eventual associations should further 
be replicated in different populations and ideally validated in 
randomized controlled trials.   
b. The ability to predict individual risk of disease or prognosis, and 
potential changes in risk in relation to modifiable environmental 
factors.  
c. The possibility of choosing the best treatment for an individual to 
maximize response or minimize side effects based on genetic 
predisposition (“pharmacogenetics”). The idea that the term 
“pharmacogenetics” conveys is more general than 
“pharmacogenomics”, which may rather be considered as “the whole-
genome application of pharmacogenetics”.  
d. There may also underlie an interesting aspect of public health impact, 
depending on the prevalence of the conditions studied (high both for 
hypertension and diabetes), the strength of the interaction, and the allele 
frequencies in the population.  
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1.G.2. Gene-environment interaction in the field of anti-hypertensive drugs 
and diabetes onset 
There seems to be overall agreement that, to reduce the rate of false discovery, 
search for gene-environment interactions should be restricted to a priori biologically 
hypotheses-driven approaches (104). 
Several reports in the medical literature describe the effect that genetic 
polymorphisms have on different endpoints (atherosclerosis, micro-albuminuria, 
nephropathy, blood pressure responsiveness, renal hemodynamics or even re-
hospitalization) in the diabetic populations as a response to anti-hypertensive drugs 
(105,106). Moreover, there is published work on how common genetic variation modifies 
the hypoglycemic response at the exposure to different oral hypoglycemic drugs 
(107,108).  
Other additional studies have focused on the interaction effects between genes 
and other environmental factors on T2DM incidence. Thus, PPAR-γ has been a 
thoroughly studied genetic locus: some -but not all- studies have demonstrated an 
interaction effect between Pro12Ala genotype and the composition of dietary fat intake 
on insulin resistance, BMI, or glycemia (109); also, results of gene–exercise interactions 
have been more consistent in showing Ala-allele carriers as being more sensitive to the 
metabolic effects of exercise (110). However, certainty about whether environmental or 
behavioral factors modify the association between variation in TCF7L2 and T2DM and 
diabetes-related quantitative traits remains to be established (76).  
Reports concerning increased or decreased T2DM incidence as secondary effects 
of antihypertensive drugs due to common genetic variation are lacking. The possible 
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modifying effect of common genetic variation on the secondary hyperglycemic effects of 
antihypertensive drugs has been only occasionally reported in the medical literature. 
Whereas hypertension and hypertension treatment, on the one hand, and genetic 
background, on the other hand, seem to increase fasting glucose and T2DM risk, it is not 
known whether these factors can modify each other’s association with glycemia. 
Eventual demonstration of gene-drug interactions might make genetic information useful 
when selecting anti-hypertensive drugs for patients at risk for developing adverse 
metabolic effects.     
 Here, we tested the hypothesis that the subsets of common SNPs associated with 
fasting glucose or T2DM that appear to influence beta-cell function interact with 
hypertension or antihypertensive drugs in their positive associations with change over 
time in fasting glucose (ΔFG) or incident T2DM. 
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2. SUMMARIZED HYPOTHESES 
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Recent well-powered studies and meta-analyses support an association for both 
thiazides and beta-blockers with risk of T2DM. Contrarily, ACE inhibitors and ARB 
appear to have neutral or even protective effects in regard to T2DM risk. Patho-
physiological responsible mechanisms are largely unknown.  
Common genetic variation has been convincingly associated with T2DM risk in 
the literature. Thus, it is a biologically plausible hypothesis that common genetic 
variation in T2DM-associated SNPs that influence beta-cell function could either enhance 
or attenuate the deleterious or beneficial effects that antihypertensive drugs exert on risk 
of T2DM or fasting glucose levels. 
We proposed to analyze the 33 autosomal SNPs so far convincingly associated 
with T2DM and the 16 SNPs so far associated with fasting glucose levels (8 overlap with 
T2DM risk), which apparently influence pancreatic beta-cell function (Table 2). Each 
one of these SNPs allows for testing drug-gene interactions associated with T2DM risk or 
change over time in fasting glucose levels, respectively.  
  Using data on antihypertensive drug exposures, occurrence of T2DM and 
plasmatic levels of fasting glucose from the Framingham Offspring Cohort, in this 
observational, longitudinal, cohort study, we thus proposed to test the following 
hypotheses: 
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PRELIMINARY HYPOTHESES 
 
 Hypertension increases T2DM risk and change over time in plasma fasting 
glucose levels as compared to no-hypertension. 
 Overall hypertension treatment increases T2DM risk and change over time in 
plasma fasting glucose levels as compared to untreated hypertension. 
 Treatment with thiazides or beta-blockers increases T2DM risk and change over 
time in plasma fasting glucose levels as compared to untreated hypertensive 
patients.  
 Treatment with ACE inhibitors or ARB decreases T2DM risk and change over 
time in levels of plasma fasting glucose as compared to untreated hypertensive 
patients.  
 Common beta cell function-influencing fasting glucose associated- and T2DM 
associated-SNPs confer higher change over time in fasting glucose and T2DM 
risk. 
 
MAIN HYPOTHESIS 
 
 Variation in novel MAGIC, DIAGRAM + and other previously reported beta cell 
function-influencing SNPs would modify the association between hypertension or 
specific hypertension treatments and T2DM risk or change over time in plasma 
fasting glucose levels.  
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3. METHODS 
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3.A. Population: The Framingham Offspring Study  
The original Framingham Heart Study was started in 1948. It recruited 5,209 
individuals, among whom there were 3,288 from 1,644 husband-wife pairs (111). The 
children of these couples and the children's spouses were invited to participate in the 
Framingham Offspring Study (112). The offspring were thought to be a desirable target 
population for several reasons: Firstly, a very high proportion of the offspring were 
thought to reside indefinitely in the New England area and would therefore be accessible 
for study. Also, many members of the offspring were close to the same age their parents 
were when they were first examined in the original Framingham Heart Study (1948-
1952) (113,114). 
Records from the first Framingham Heart Study exam were utilized to construct a 
roster of families to be contacted. Attempts were made to contact the parent by telephone 
to obtain address information on all children. When no contact could be made with a 
parent, relatives, friends or neighbors were asked to supply this information about the 
children. In only 42 instances (2.6%) was it impossible to determine whether there were 
descendants of the FHS spouse pair. An additional 198 pairs were known to be childless. 
Thus, 1,404 couples were known to have had at least one child and 1,202 of these 
families (86%) are represented by at least one child in the study. The 1,202 mothers gave 
birth to or adopted 3,717 children, of which 2,656 (71%) were examined in this study. All 
offspring of eligible parents were asked to participate, regardless of the size of the family 
(112).  
Invitations to participate in the study were also sent to a special group of children 
who had one parent in the Framingham Heart Study who had either coronary heart 
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disease or who exhibited abnormal lipoprotein patterns at the tenth biennial examination 
of the original cohort. This resulted in the examination of an additional 899 offspring of 
378 parents. Also, 1,644 spouses of examined offspring were invited for examination. Of 
these, both members of 144 spouse pairs are offspring of the original cohort (112). This 
added up to 5,124 people who agreed to participate. For this analysis, we only initially 
included 2,922 non-diabetic individuals for whom complete clinical and genotype data 
were available. Participants were essentially of white European ancestry.  
Examinations of the offspring started in September, 1971, and were completed in 
July, 1975. Participants have been seen in the clinic about every 4 years (up to 8 exams), 
except for the ~8-year period between exams 1 and 2, to receive a complete medical 
history and physical exam, including anthropometric measurement and blood sample 
collection. Subjects were asked about their medical history, use of medication, alcohol 
consumption and history and current use of tobacco. All subjects reporting a history of 
cardiovascular disease or specific symptoms of coronary heart disease or peripheral 
vascular disease were examined by a cardiologist (115). The outcomes of this exam as 
well as previous hospital or physician records were used in the standardized diagnosis of 
cardiovascular disease (113,114). Over 80% of the eligible offspring were still living in 
New England 7 years after the constitution of the study cohort.  
Electrocardiography (ECG) measurements, anthropometric measurements, blood 
pressure and skin fold measurements were also obtained from all subjects. Fasting blood 
specimens were used for lipoprotein quantification including electrophoresis and 
hematological observations. Whenever possible, the study protocol called for procedures 
identical to those used in the recent examinations of the FHS cohort (112).  
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3.B. Data collection and variables coding in the Framingham Offspring Study  
 When subjects were examined in the Framingham Offspring Study, the 
information collected for each exam did not exactly overlap in previous exams: whereas 
the first exam reported 183 items, the seventh exam requested information on 712 
variables, as information concerning exposure to medications, physical activity, behavior, 
laboratory data and outcomes became more detailed. Exam 8 focused on outcomes.  
3.B.1. Drug exposures 
To understand the variability of the information collected at each exam, especially 
in the oldest ones, we can compare how information was retrieved from exams 1 and 7 in 
regard to anti-hypertensive medication (Appendix 1). For instance, detailed information 
on drug exposures is missing for the first exam; in subsequent exams, a more thorough 
collection of information on drug exposures was done. Complete information on use of 
beta-blockers and other anti-hypertensive drugs became available at exam 2, and on ACE 
inhibitors at exam 3. This information is summarized in Table 5. 
Table 5. Anti-hypertensive drugs exposures at each exam in the Framingham Offspring Study.  
 Exam 1 Exam 2 Exam 3 Exam 4 Exam 5 Exam 6 Exam 7 Exam 8 
Hipertension  Y/N Y/N Y/N Y/N Y/N Y/N Y/N Y/N 
Systolic BP Level Level Level Level Level Level Level Level 
Treatment for high BP  Y/N Y/N Y/N Y/N Y/N Y/N Y/N Y/N 
Diuretics  Y/N Y/N Y/N Y/N Y/N Y/N Y/N Y/N 
      Thiazides    Y/N Y/N Y/N Y/N Y/N  
      Other diuretics    Y/N Y/N Y/N Y/N Y/N  
      Potassium supplement    Y/N Y/N Y/N Y/N Y/N  
Beta-blockers   Y/N Y/N Y/N Y/N Y/N Y/N  
       Type of beta-blocker   Y/N   Y/N Y/N Y/N  
Calcium-channel blockers    Y/N Y/N Y/N Y/N Y/N  
ACE inhibitors or ARB    Y/N Y/N Y/N Y/N Y/N  
“Other hypotensives”  Y/N Y/N Y/N Y/N Y/N Y/N Y/N Y/N 
 
Blank spaces: information not available. Y/N: information coded as “Yes” or “No”. BP: blood pressure. 
Interval between exam 1 and 2 was excluded from our analysis. 
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3.B.2. Covariates 
Tables 6-8 show the information on some of the covariates that is available at 
each exam:  
 
  Table 6. Information on clinical covariates available in the Framingham Offspring Study.  
 
Age, 
sex 
Parents in FHS Parental T2DM Hypertension BP Diabetes BMI Waist  
Exam1 YES YES  YES YES YES YES  
Exam2 YES   YES YES YES YES  
Exam3 YES   YES YES YES YES  
Exam4 YES   YES YES YES YES YES 
Exam5 YES   YES YES YES YES YES 
Exam6 YES  YES YES YES YES YES YES 
Exam7 YES   YES YES YES YES YES 
Exam8 YES  YES YES YES YES Weight  
  
FHS: Framingham Heart Study. BP: blood pressure levels. BMI: body mass index. Waist: waist perimeter 
measured.  
“YES” denotes data available for that variable at that particular exam. 
 
 
Table 7. Information on behavior patterns and other covariates in the Framingham Offspring Study. 
 
Physical 
activity 
Smoking Alcohol 
Potassium 
supplementation 
Use of steroids 
Exam 1  YES YES YES  
Exam 2 YES YES YES YES  
Exam 3  YES YES YES YES 
Exam 4 YES YES YES YES YES 
Exam 5 YES YES YES YES YES 
Exam 6  YES YES YES YES 
Exam 7 YES YES YES YES YES 
Exam 8  YES    
  
Alcohol intake is measured in ounces per week. HDL: high density lipoprotein. TG: triglycerides.  
“YES” denotes data available for that variable at that particular exam. 
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Table 8. Information on some basic laboratory data in the Framingham Offspring Study. 
  Glucose HbA1C OGTT HDL TG eGFR 
Exam1 YES   YES YES  
Exam2 YES   YES YES  
Exam3 YES   YES YES  
Exam4 YES   YES YES  
Exam5 YES YES YES YES YES YES 
Exam6 YES   YES YES  
Exam7 YES YES YES YES YES  
Exam8 YES    YES  
 
OGTT: oral glucose tolerance test. HDL: high density lipoprotein. TG: triglycerides. eGFR: estimated 
glomerular filtration rate.  
“YES” denotes data available for that variable at that particular exam. 
 
 
 For co-morbidities, information was collected on those previously known 
coexisting conditions that might have made physicians preferentially use some anti-
hypertensive medications over others. These previous conditions included coronary heart 
disease, renal insufficiency, chronic heart failure, stroke and lower limb intermittent 
claudication. We used the dataset called “sequence of events” in the Framingham Study, 
specifically constructed to compile information on the following outcomes: coronary 
heart disease, cerebrovascular accident, chronic heart failure, intermittent claudication 
and death (for instance, coronary heart disease was coded as shown in Appendix 2). By 
Dec 31, 2008, a total of 3,980 cardiovascular events in 1,915 subjects had been reported 
in the Framingham Offspring Study. 
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3.C. Genotype and imputation 
3.C.1. Genotype in Framingham 
While pursuing the Framingham Study's established research goals, the NHLBI 
and the Framingham investigators expanded their research mission into the study of 
genetic factors underlying cardiovascular disease and other disorders. Over the past two 
decades, DNA has been collected from blood samples and from immortalized cell lines 
obtained from Original Cohort participants, members of the Offspring Cohort and the 
Third Generation Cohort. Genome-wide linkage analysis has been conducted using 
genotypes of approximately 400 microsatellite markers that have been completed in over 
9,300 subjects in all three generations. For other recent collaborative projects, thousands 
of SNP have been genotyped for candidate gene regions in subsets of FHS subjects with 
available DNA (116). 
In 2007, the FHS conducted the genotyping for the FHS SHARe (SNP Health 
Association Resource) project, using approximately 550,000 SNPs (Affymetrix 500K 
mapping array plus Affymetrix 50K supplemental array) in over 9,300 subjects from the 
three generations of subjects (117). The SHARe database is housed at NCBI's dbGaP and 
contains all 550,000 SNPs as well as SNP and microsatellite genotyping conducted 
previously in the Framingham Heart Study. The phenotype database contains a vast array 
of phenotype information available in all three generations. These include: quantitative 
measures of the major risk factors, such as systolic blood pressure, total and HDL 
cholesterol, fasting glucose, and cigarette use; anthropomorphic measures, such as body 
mass index; and so on. Many of these measures have been collected repeatedly in the 
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original and Offspring cohorts. It is interesting to highlight that genome-wide data are 
publicly available in Framingham.  
Genotypes for this study were obtained from the Affymetrix array data available 
in the FHS-SHARe dataset (116) or from de novo genotyping on the iPLEX (Sequenom) 
platform (118), when not included in the Affymetrix array. Albeit there is evidence of 
population sub-stratification in Framingham, there was no evidence of inflation of the 
type-I error rate due to population stratification for most traits in previous studies (89).  
 
3.C.2. Blood samples treatment for DNA extraction in Framingham 
Treatment of blood samples for DNA extraction followed standard procedures, 
which have been reported elsewhere (119) (here, summarized in Appendix 3).  
 
3.C.3. Control filters for genotype quality in Framingham 
There are well-established control filters for quality of genotyping. “Minor allele 
frequency” (MAF) is the frequency of the SNP’s less frequent allele in a given 
population. Common genetic variants have MAF >5%, whereas rare variants have 
MAF<5%, or even <1%. The “call rate” is another control filter, which is defined as the 
proportion of samples for which genotypes are obtained for a converted marker (120). 
The genotyping-calling algorithm used in Framingham for Affymetrix was BRLMM 
(“Bayesian robust linear modeling using Mahalanobis distance”) (89), which did not 
appear to have a calling bias against heterozygotes (121).  
An additional control filter is the “Hardy-Weinberg equilibrium” (HWE), defined 
as the stable frequency distribution of genotypes (AA, Aa, and aa) in the proportions p2, 
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2pq, and q2, respectively (where p and q are the frequencies of the alleles, A and a) that is 
a consequence of random mating, in the absence of mutation, migration, natural selection 
or random drift (122). Lastly, as an additional control filter in our sample, individuals 
with more than 1,000 Mendelian errors were excluded. For the SNPs genotyped, MAF 
were >5% and minimum call rates were 97% for Affymetrix and 96.9% for iPLEX SNPs. 
All SNPs were in HWE (P>10-6 for Affymetrix and P>0.02 for iPLEX).  
 
3.C.4. SNP imputation in Framingham 
For several candidate SNPs, genotyping was actually not done; “proxies” can be 
alternatively used for these SNPs, which are other SNPs in the same genetic region that 
are in linkage disequilibrium (LD) with the putative SNPs. However, it is not uncommon 
that a proxy for the candidate SNP has not been assayed either, what makes it necessary 
to use some techniques as an attempt to predict which alleles the candidate SNP can 
actually have (123). With this aim, the information provided by the HapMap2 haplotypes 
has been very valuable for samples with a similar ancestry to populations included in the 
HapMap panels, the reference ones (124).  
Imputation in Framingham has been performed with MACH software (123). In 
Tables 9 and 10, we can see which SNPs were actually genotyped or imputed for T2DM 
and fasting glucose in Framingham. Quality of predictions from imputations can easily be 
measured by initially masking the genotypes and then evaluating the results (123). The 
most likely predicted genotype above some threshold can be compared with the true 
genotype and a plot of the percentage discordance versus the percentage of missing 
genotypes can be constructed for a range of thresholds to illustrate performance (125). 
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The error rate of the “best guess” genotype for various methods can thus be estimated 
(126). Our imputation method has been shown to produce well-calibrated probabilities 
(127). Some issues have been raised from previous studies comparing the performance of 
the several imputation methods, however: firstly, imputation error rate increases as the 
minor allele frequency decreases (124); and secondly, differences in genetic diversity 
between the study population and the reference panel can also influence imputation 
accuracy (128).   
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Table 9. Genotyped and imputed beta cell T2DM-associated SNPs . 
SNP Chromosome Nearest gene Genotyped/Imputed Platform Variance ratio 
rs10923931 1 NOTCH2 I iPLEX 1.010411  
rs340874 1 PROX1 I iPLEX 0.711865 
rs780094 2 GCKR G Affymetrix   
rs7578597 2 THADA G Affymetrix   
rs243021 2 BCL11A I iPLEX 0.967461 
rs7593730 2 RBMS1/ITGB6  G Affymetrix 1.009913 
rs11708067 3 ADCY5 I iPLEX 0.936832 
rs1470579 3 IGF2BP2 I iPLEX 1.0221  
rs10010131 4 WFS1 I iPLEX 1.010443 
rs4457053 5 ZBED3 I iPLEX 0.888613 
rs7754840 6 CDKAL1 G Affymetrix   
rs9472138 6 VEGFA G Affymetrix   
rs2191349 7 DGKB/TMEM195 I iPLEX 0.973185 
rs864745 7 JAZF1 G Affymetrix   
rs4607517 7 GCK I iPLEX 0.994926 
rs896854 8 TP53INP1 I iPLEX 0.954928 
rs13266634 8 SLC30A8 I iPLEX 0.328816 
rs10811661 9 CDKNA/2B G Affymetrix   
rs13292136 9 TLE4 (CHCHD9) I iPLEX 0.953989 
rs12779790 10 CDC123,CAMK1D I iPLEX 0.768427 
rs1111875 10 HHEX I iPLEX 0.996042 
rs7903146 10 TCF7L2 I iPLEX 0.989887 
rs2334499 11 HCCA2 I iPLEX 0.738763 
rs231362 11 KCNQ1 I iPLEX 0.680838 
rs5215 11 KCNJ11 G Affymetrix   
rs1552224 11 CENTD2 I iPLEX 0.919218 
rs10830963 11 MTNR1B I iPLEX 0.696892 
rs1153188 12 DCD G Affymetrix   
rs7961581 12 TSPAN8,LGR5 G Affymetrix   
rs7957197 12 OASL/TCF1/HNF1A I iPLEX 0.974055 
rs11634397 15 ZFAND6 I iPLEX 0.921906 
rs8042680 15 PRC1 I iPLEX 1.029531 
rs757210 17 HNF1B/TCF2 I iPLEX 0.202485 
 
G: actually genotyped. I: imputed. Only one SNP (rs757210) had a variance ratio <0.3 (highlighted in red). 
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As a control filter for imputation, it is common practice to refer to the variance 
ratio, which is defined as the ratio of the empirically observed variance (based on the 
imputation) to the expected binomial variance p (1-p), where p is the minor allele 
frequency (129); for the imputed SNPs in our study, the variance ratio was >0.3, except 
for rs757210, a T2DM SNP, at HNF1B (variance ratio=0.20) (Table 9); the median 
variance ratio was 0.94 for the T2DM SNPs and 0.98 for the quantitative-traits SNPs.  
 
 
 
Table 10. Genotyped and imputed beta cell fasting glucose-associated SNPs . 
SNP Chromosome Nearest gene Genotyped/Imputed 
 
Platform Variance ratio 
rs340874 1 PROX1 I  iPLEX 0.711865 
rs560887 2 G6PC2 I  iPLEX 0.991368 
rs780094 2 GCKR G  Affymetrix   
rs11708067 3 ADCY5 I  iPLEX 0.936832 
rs11920090 3 SLC2A2 I  iPLEX 0.995684 
rs2191349 7 DGKB/TMEM195 I  iPLEX 0.973185 
rs4607517 7 GCK I  iPLEX 0.994926 
rs13266634 8 SLC30A8 I  iPLEX 0.328816  
rs7034200 9 GLIS3 I  iPLEX 0.986822 
rs10885122 10 ADRA2A I  iPLEX 0.948183 
rs7903146 10 TCF7L2 I  iPLEX 0.989887  
rs11605924 11 CRY2 I  iPLEX 0.998308 
rs7944584 11 MADD G  Affymetrix   
rs174550 11 FADS1 I  iPLEX 0.991725 
rs10830963 11 MTNR1B I  iPLEX 0.696892 
rs11071657 15 FAM148B (C2CD4B) I  iPLEX 0.674072 
 
G: actually genotyped. I: imputed. In bold, overlapping fasting glucose- and T2DM-SNPs. 
 
 
 
  
80 
 
3.D. Statistical methods 
 3.D.1. Definitions 
We defined diabetes mellitus as having a fasting plasma glucose ≥126 mg/dl (7.0 
mmol/l) at any exam or diabetes treatment at any exam. We did not use HbA1C to define 
diabetes. More than 99% of the cases of diabetes among the participants in the 
Framingham Offspring Study are T2DM (130). We defined a positive self-reported 
family history of diabetes as a report that one or both parents had diabetes; this definition 
is more than 56% sensitive and 97% specific for confirmed parental diabetes (131). 
Hypertension was defined as either following treatment for hypertension or 
elevated blood pressure at any exam, according to the recommendations of the Seventh 
Report of the Joint National Committee on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure (systolic blood pressure ≥140 mm Hg or diastolic 
blood pressure ≥90 mm Hg) (14). In the Framingham Offspring Study, blood pressure 
was determined by at least two separate measurements carried out by physicians -for 
exams 1 and 2, a blood pressure measurement by a nurse was also available-, and the 
mean value was calculated; subjects had been seated for at least 5 minutes before blood 
pressure measurement (132). At each exam, we defined “no hypertension” as not on 
treatment and normal blood pressure, according to the recommendations of the Seventh 
Report of the Joint National Committee on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure (systolic blood pressure <140 mm Hg or diastolic 
blood pressure <90 mm Hg) (14). Untreated hypertension was defined as not on treatment 
for hypertension but with elevated blood pressure (systolic blood pressure ≥140 mm Hg 
or diastolic blood pressure ≥90 mm Hg).  
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Current smoking was defined as consuming at least 1 cigarette per day within 1 
year of the index examination. Weight, measured to the nearest pound, was obtained with 
the participant wearing a gown without slippers or shoes. To calculate body mass index 
(BMI), we divided weight in kilograms by height in meters squared.  
 
3.D.2. Laboratory determinations 
Fasting glucose was measured in fresh plasma with a hexokinase reagent kit (A-
gent glucose test; Abbott, South Pasadena, CA). Glucose assays were run in duplicate; 
intra-assay coefficients of variation were around 3% (133). The fasting total plasma 
cholesterol and triglycerides were measured enzymatically, and the HDL cholesterol 
fraction was measured after precipitation of low-density and very low-density 
lipoproteins with dextran sulfate-magnesium (134).  
Insulin was measured in EDTA plasma as total immunoreactive insulin (Coat-A-
Count Insulin; Diagnostic Products, Los Angeles, CA). Cross-reactivity of this assay with 
proinsulin at midcurve is around 40%, the intra-assay and inter-assay coefficients of 
variation ranged from 5.0 to 10.0%, and the lower limit of sensitivity was 8 pmol/l. 
HbA1C was measured only at exam 5 (1991-1994) by high-performance liquid 
chromatography after an overnight dialysis against normal saline to remove the labile 
fraction.  
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3.D.3. Statistical analyses  
3.D.3.1. Sequence of actions  
Step 1: We defined three “hypertension exposure” classifications. We classified 
individuals at each exam as:  
 Having or not having hypertension. 
 Having medication-treated hypertension or untreated hypertension. 
 Among those treated, into medication treatment groups: we classified individuals 
on hypertensive treatment into five mutually exclusive antihypertensive drug 
exposure groups: thiazides only; beta-blockers only; ACE inhibitors/ARB only; 
any combination of the previous three classes; and “other” hypertensive therapies 
(calcium-channel blockers, reserpine derivatives, methyldopa, alpha-1 agonists, 
alpha-2 blockers, and peripheral vasodilators) (Figure 5). 
 
Figure 5. Visual representation of the anti-hypertensive drug exposures in the hypertensive 
subjects 
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A
B
AC
BC
ABC
Untreated hypertensives
C
AB
Other anti-hypertensives
E
D
83 
 
 
We believed that the comparison between “pure” exposures (thiazides only; beta-
blockers only; ACE inhibitors/ARB only; any combination of the previous three classes; 
and “other”) vs. untreated hypertensive subjects would yield the most interesting results 
on a clinical basis, though at the expense of possibly jeopardizing the statistical power of 
our sample. Alternative hypotheses could have been to compare “mixed” exposures (i.e., 
for thiazides, [A+AB+AC+ABC] in Figure 5) vs. untreated hypertensive subjects; or to 
compare each exposure drug vs. treated hypertensive subjects receiving alternative 
treatments (i.e., thiazides exposure vs. treatments other than thiazides: 
[A+AB+AC+ABC] vs. [B+BC+C+D] in Figure 5; and so on).  
 
Step 2: We evaluated the baseline characteristics of the population included in 
our study (natural, demographic, coexisting conditions), using the chi-square test to 
compare dichotomous variables and the T-test to compare means for continuous 
variables. 
 
Step 3: We next defined the genetic exposures. To assess genetic influences on 
change in fasting glucose levels, we used 16 fasting glucose-associated SNPs reported to 
influence beta-cell function (89,96). For risk of T2DM, we only used 33 out of 40 
T2DM-associated SNPs thought to influence beta-cell function (80-92). As mentioned 
earlier, all SNPs were selected from large studies showing robust, replicated statistical 
association.  
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In order to overcome the issues of limited statistical power and multiple testing, 
we decided to use the two lists of SNPs to build a16-fasting glucose-beta cell SNP 
genetic risk score, and a 33 T2DM-beta cell SNP genetic score (8 SNPs overlapped), 
modeled as additive weighted genetic scores. According to our main hypothesis, we 
evaluated the association of the fasting glucose-SNP genetic score with change over time 
in fasting glucose, and the association of the T2DM-SNP genetic score with risk of 
incident T2DM.  
For the construction of the 16-fasting glucose SNP and the 33-T2DM SNP 
additive weighted genetic risk scores, we counted risk alleles (0,1,2) for each genotyped 
SNP -or its dosage, when imputed- and multiplied each SNP genotype by its published 
beta coefficient for unit increase in fasting glucose or in diabetes risk (89,90). We used 
the ORs for T2DM risk from the replication stages of the large GWAS, when the 
associations were replicated or found in GWAS; for those SNPs that were not replicated 
in the large GWAS, we used the ORs from the replication stages of the discovery 
publications. For FG, we used the beta effects reported by Dupuis et al. (89).  
We added up the product of that multiplication at each SNP, divided the sum by 
twice the sum of the betas and multiplied the result by the number of SNPs. The genetic 
scores can be interpreted as a measure of beta-cell frailty due to having been built by 
means of counting SNPs with deleterious effects on glycemia putatively mediated by 
impaired beta cell biology. This approach by building genetic risk scores has been used 
extensively in previous work (135). 
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Step 4: We tested the association of hypertension, hypertension treatment and 
specific antihypertensive drug exposures with the outcomes: change over time in fasting 
glucose levels (calculated as fasting glucose end minus beginning of each time period) or 
risk of T2DM. We analyzed change in fasting glucose and T2DM risk as a function of 
baseline hypertension category and genetic status using a pooled regression approach, in 
age-, sex-adjusted models (136): we pooled clinical data from the 2,922 non-diabetic 
individuals for whom complete clinical data for all variables were available at every 
exam into 6 time (~4-year) periods (exams 2-3, 3-4, 4-5, 5-6, 6-7 and 7-8). We thus 
generated 15,852 person-observations pertaining to 6 time periods, with a mean pool 
length of 4.15 years over a maximum of 28.3 years of study follow up.  
As a result of pooling, the information from each individual for the start point of 
each time period contributed independently from the information belonging to a different 
time period. This way, the possibility of switching treatments and changes in covariates 
over time -like, for instance, body weight- could be accounted for. This method, named 
“pooled logistic regression” or “logistic regression with pooled repeated measures” has 
been widely used in Framingham (135,137) and has been shown to produce similar point 
estimates and variances as time-dependent covariate Cox regression analysis, provided 
that the exams are separated by relatively short time periods, that the outcome is 
relatively uncommon, and that people who develop the outcome are excluded from the 
following observation period (138).  Odds Ratios can overestimate the relative risks in 
case disease prevalence increases.  
To test change over time (~4-year) in fasting glucose levels, we used age-, sex-, 
baseline fasting glucose-adjusted Generalized Estimating Equations (GEE) models with 
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the FAM IDENTITY link function (139). For ~4-year risk of incident T2DM, we used 
age-, sex-adjusted pooled logistic regression GEE models (LOGIT link). Use of GEE 
with family identity as the clustering unit allowed us to account for correlated 
observations in individuals within families. GEE method simultaneously analyzes the 
cross-sectional relationship between each of the independent variables and change in 
fasting glucose or incident T2DM, and the relationship between changes in these 
variables and changes in fasting glucose or incident T2DM over time. The REPEATED 
and SUBJECT options in PROC GENMOD allow accounting for correlated observations 
in both family and individual identities.  
We excluded diabetes cases at baseline of each time period. For the change over 
time in fasting glucose analyses, we additionally excluded people who had started 
diabetes treatment within a given time period. 
Step 5: Our main hypothesis was to evaluate whether common SNPs associated 
with fasting glucose or T2DM that appear to influence beta-cell function interact with 
hypertension or antihypertensive drugs in their positive associations with: 1) ~4-year 
change in fasting glucose, and 2) ~4-year risk of incident T2DM. 
Thus, to analyze whether hypertension categories and genetic scores interact to 
influence change over time in fasting glucose or incident T2DM beyond main effects, we 
tested first-order interaction terms between hypertension, antihypertensive treatment or 
specific drug-exposures and each genetic score. Interaction terms took the form: trait = 
β0 + βc*covariates + β1*E + β2*SNP + β3*E*SNP + ε, where E represented drug 
exposure and SNP denoted genetic contributions. The result of interest was the P value 
for the test H0: β3 =0. In this way, we tested our primary hypothesis that the aggregate 
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genetic risk for -cell dysfunction interacted with drug exposure to determine change in 
fasting glucose and risk of T2DM. Visual representations of hypothetical interaction 
effects between a drug exposure and an individual SNP or a genetic risk score on fasting 
glucose levels are shown in figure 6.  
Figure 6: Visual representation of the proposed hypothetical interaction effects between an anti-
hypertensive treatment and an individual SNP or the genetic risk score, for fasting glucose levels. 
 
Figure 6.1. Association drug exposure-trait before and after genotype-adjustment 
 
When the model is additionally adjusted for covariates that can explain part of the effect (i.e., genotype), 
the marginal effect is weaker (thus, the slope for the pink marks is flatter than for the blue marks). 
 
Figure 6.2. Interaction among drug exposure and SNP 
 
Across the spectrum of different values of the genotype, the effect that the exposure exerts on the 
trait differs. This is an example of statistical interaction: depicted lines are not parallel. 
 
80
90
100
110
120
130
140
0 1 2 3
Crude
Adjusted
80
90
100
110
120
130
140
150
160
170
No drug
exposure
Drug
exposure
AA genotype
Ab genotype
bb genotype
Fasting 
glucose 
Crude: FG=α+β1Rx 
Adj. for genotype: FG: α+β1Rx+β2Ab+β3AA 
We test Ho: β2=β3=0 
 
Fasting 
glucose 
FG: α+β1Rx+β2Ab+β3AA+β4Rx*Ab+β5Rx*AA 
We test Ho: β4=β5=0 
New interaction terms (in blue) are entered in the 
regression formula 
88 
 
 
 
Figure 6.3. An additive interaction effect is present between drug exposure and the genetic risk score 
in the lower pannel (abscissa axis fasting glucose in mg/dl). 
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Step 6: In a priori specified secondary analyses, we evaluated joint models 
without interaction terms to test the hypotheses that, in case no interactions were found, 
hypertension or antihypertensive treatments and the genetic scores had independent 
associations with ΔFG, or incident T2DM.  
 
Step 7: In additional secondary analyses, we tested associations in models with 
additional adjustment for T2DM risk factors measured at the baseline of each period 
(mean blood pressure, body mass index, smoking, plasma high-density lipoprotein (HDL) 
and triglyceride (TG) levels (both per mg/dl), and self-reported alcohol consumption 
(ounces per week)) to see whether these confounders altered observed associations.  
 
Statistical analyses were performed using SAS software, version 9.2 (SAS 
Institute, Cary, NC). An empirical p value <0.05 indicated statistical significance for 
interaction terms or main effects, as we established one hypothesis for change over time 
in fasting glucose, and a separate one for T2DM risk. 
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Figure 7. Flow-chart showing the sequential steps in the statistical analysis . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Define the three “hypertension-exposure” classifications  
Step 1 
1. Hypertension vs. no hypertension 
2. Hypertension treatment vs. untreated hypertension 
3. Five mutually-exclusive hypertension treatment categories 
Step 2 
Define the genetic exposures: 16 fasting glucose-SNPs and 33 T2DM-SNPs 
 
Step 3 
Describe the baseline characteristics of the population  
Evaluate association with outcomes (change in fasting glucose, T2DM),  
in stratified analyses using GEE, according to:  
 hypertension  
 hypertension treatment  
 specific hypertension treatment categories 
 genetic exposures (individual SNPs, and genetic risk scores) 
Construction of two weighted additive genetic risk scores: 
A 16-SNP fasting glucose weighted genetic risk score 
A 33-SNP T2DM weighted genetic risk score 
 
Step 4 
Build age-, sex-adjusted pooled regression models  
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Step 5 
Step 6 
Step 7 
Seek first-order interaction effects between: 
 
Hypertension, hypertension treatment, or specific drug exposures 
* 
16-fasting glucose SNP or 33-T2DM SNP genetic risk scores 
on 
~4-year change in fasting glucose levels, or ~4-year risk of incident T2DM 
 
Look for independent associations of: 
 
 hypertension or its treatments and genetic exposures 
in joint models without interaction terms  
with change in fasting glucose or T2DM risk 
 
Secondary analyses in fully-adjusted models for  
additional risk factors for T2DM 
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3.D.4. Statistical power to detect hypertension-genetic score and drug exposure-
genetic score interaction 
Only for very weak marginal effects (OR≈1.2) and at least moderate interactions 
(OR≈1.5), interactions are detectable with smaller sample sizes than the marginal effects. 
Rather, usually larger sample sizes are needed to detect interaction effects.  
We performed estimations of the study power for the gene-environment 
interaction tests using Quanto software, version 1.2.4 (140), prior to conducting the 
association analyses, in an attempt to calculate the statistical power that we had with the 
Framingham Offspring Study population. We estimated statistical power for the 
hypertension vs. no hypertension analysis, and for the beta-blockers exposure vs. 
untreated hypertensive, as an example of specific drug exposure analysis. In age-, sex-
adjusted models, sample sizes in our study varied between 14,673 for change in fasting 
glucose and 15,852 for T2DM risk in the hypertension vs. no hypertension analyses, and 
between 4,492 for change in fasting glucose and 4,900 for T2DM risk in the specific drug 
exposure analyses. 
According to previously published data, we assumed an additive genetic model 
using an average per-allele effect size of 0.45 mg/dl on fasting glucose (89), and an 
average per-allele relative risk of 1.15 for incident T2DM (90), interacting with binary 
environmental exposures with effect sizes of 3.24 mg/dl for hypertension and of 0.011 
mg/dl for beta-blockers exposure in the change in fasting glucose analyses, and relative 
risks of 2.4 for hypertension, and 1.28 for beta-blockers exposure in the T2DM analyses 
(37). 
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 We had 80% statistical power, with a type I error of 0.05 in two-tailed analyses, 
and for allele frequencies between 20% and 80%, to detect regression coefficients 
ranging from 0.04 to 0.05 for the genetic score-hypertension interaction tests, and from 
0.10 to 0.12 for the genetic score-beta blockers exposure interaction test in the change in 
fasting glucose analyses, and coefficients ranging from 1.07 to 1.08 for the genetic score-
hypertension interaction tests, and from 1.19 to 1.23 for the genetic score-beta blockers 
exposure interaction test in the T2DM analyses. 
  
3.D.5. Permissions and institutional review board approval 
All participants gave written informed consent. The study protocols were 
approved by the Institutional Review Board at the Boston University Medical Center. 
Use of SHARe information by this author was allowed by the National Center for 
Biotechnology Information Genotypes and Phenotypes Database (NCBI dbGaP) Data 
Access Request system at the National Institutes of Health (141), on May 3, 2010.  
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4. RESULTS 
95 
 
4.A. Base-line characteristics of the study population 
 Mean age was 51.9 years, and women constituted 53.8% of our study population. 
As people in the Framingham Offspring Study aged, BMI increased and hypertension and 
hypertension treatment became more prevalent, but less people were smokers (Table 11).  
 
Table 11. Base-line characteristics of the Framingham Offspring Study population at each exam (exam 1 excluded). 
 
 
Exam 2 
(1979-1983) 
Exam 3 
(1983-1987) 
Exam 4 
(1987-1991) 
Exam 5 
(1991-1995) 
Exam 6 
(1995-1998) 
Exam 7 
(1998-2001) 
 
 
Number of subjects (n) 
Mean or n 
(§SD or %) 
2,622 
Mean or n 
(SD or %) 
2,841 
Mean or n 
(SD or %) 
2,867 
Mean or n 
(SD or %) 
2,681 
Mean or n 
(SD or %) 
2,581 
Mean or n 
(SD or %) 
2,273 
Age, years 43.4 (9.9) 47.6 (9.9) 50.6 (9.8) 54.0 (9.8) 57.9 (9.6) 59.8 (9.1) 
Male sex, (%) 1,243 (47.4) 1,353 (47.6) 1,339 (46.7) 1,218 (45.4) 1,167 (45.2) 1,000 (44.0) 
Family history of diabetes  469 (17.9%) 508 (17.9%) 515 (18.0%) 482 (18.0%) 468 (18.1%) 388 (17.1%) 
*Systolic blood pressure 121 (16) 122 (16) 125 (18) 125 (18) 127 (9) 125 (18) 
Diastolic blood pressure 77 (10) 79 (10) 79 (10) 74 (10) 76 (5) 74 (10) 
Blood pressure drugs (%) 232 (8.9%) 400 (14.1%) 432 (15.1%) 428 (16.0%) 631 (24.5%) 640 (28.2%) 
Hypertension, (%) 520 (19.8%) 775 (27.3%) 910 (31.8%) 819 (30.6%) 973 (37.7%) 903 (39.8%) 
†BMI, kg/m2 25.7 (4.2) 26.0 (4.5) 26.6 (4.8) 27.1 (4.7) 27.5 (4.9) 27.7 (5.0) 
Smoking, (%) 955 (36.5%) 887 (31.3%) 729 (25.5%) 509 (19.0%) 450 (17.5%) 333 (14.9%) 
‡HDL cholesterol, mg/dl 49.0 (13.4) 51.9 (14.8) 50.2 (14.7) 51.0 (15.0) 52.2 (16.1) 55.4 (17.0) 
Triglycerides, mg/dl 100.5 (83.2) 115.5 (89.7) 117.2 (88.1) 140.7 (105.3) 134.3 (88.6) 128.6 (80.4) 
Fasting glucose, mg/dl 95.9 (9.4) 91.1 (9.2) 90.8 (9.1) 94.8 (9.6) 96.7 (9.8) 96.8 (9.6) 
Alcohol, ounces/week 3.6 (4.8) 3.3 (4.7) 2.9 (4.2) 2.6 (3.7) 2.4 (3.6) 2.7 (3.7) 
 
* Blood pressure: in mmHg. †BMI: body mass index. ‡HDL: high density lipoprotein. §SD: standard deviation. 
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Also, the prevalence of co-existing medical conditions increased with aging (Table 12). The pattern  
of anti-hypertensive drug treatment showed two peaks in the case of beta-blockers and thiazides, and  
RAS system agents use followed a lineally ascending trend (Figure 8). 
 
 
 
Table 12. Co-existing conditions and incident T2DM in Framingham Offspring Study at each exam (exam 1  excluded). 
 
 
Exam 2 
(1979-1983) 
Exam 3 
(1983-1987) 
Exam 4 
(1987-1991) 
Exam 5 
(1991-1995) 
Exam 6 
(1995-1998) 
Exam 7 
(1998-2001) 
 
Mean or n 
(‡SD or %) 
Mean or n 
(SD or %) 
Mean or n 
(SD or %) 
Mean or n 
(SD or %) 
Mean or n 
(SD or %) 
Mean or n 
(SD or %) 
Cardiovascular disease, (%) 74 (2.8%) 146 (5.1%) 161 (5.6%) 177 (6.6%) 209 (8.1%) 197 (8.7%) 
Coronary heart disease, (%) 54 (2.1%) 107 (3.8%) 117 (4.1%) 118 (4.4%) 143 (5.5%) 132 (5.8%) 
Chronic heart failure, (%) 1 (0.0%) 4 (0.1%) 4 (0.1%) 8 (0.3%) 15 (0.6%) 12 (0.5%) 
Intermitent claudication, % 16 (0.6%) 31 (1.1%) 37 (1.3%) 50 (1.9%) 52 (2.0%) 45 (2.0%) 
Beta-blockers users, (%) 56 (2.1%) 190 (6.7%) 189 (6.6%) 147 (5.5%) 214 (8.3%) 252 (11.1%) 
Thiazides users, (%) 170 (6.5%) 235 (8.3%) 186 (6.5%) 73 (2.7%) 102 (4.0%) 148 (6.5%) 
RAS users, (%) - 8 (0.3%) 90 (3.1%) 152 (5.7%) 246 (9.6%) 291 (12.8%) 
       
Incident diabetes cases  32 39 75 91 70 115 
 
*Denote prevalence, not incidence. †RAS: renin-angiotensin agents. ‡SD: standard deviation.  
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Figure 8. Pattern of use of anti-hypertensive drugs along time (percentages). 
 
 
People with hypertension were older, more frequently male and had higher BMIs 
and worse lipid profiles than people without hypertension (Table 13). 
 
Table 13. Base-line characteristics stratified by hypertension status. 
  Hypertension status 
  
   
  Yes (*HTN=1) No (HTN=0) 
  
Number of subjects (n) 4,900 10,952 
  
  Mean (§Std. Dev.)  Mean (Std. Dev.)  p-value 
 
 
Age, years 57.8 (10.0)  49.3 (10.7)  <.0001  
 
 
Male sex, % 52.1 (0.5)  43.4 (0.5)  <.0001  
 
 
†BMI, kg/m2 28.5 (5.1)  26.0 (4.3)  <.0001  
  
Smoking, % 19.1 (0.4)  26.9 (0.4)  <.0001  
 
 
‡HDL cholesterol, mg/dl 49.8 (15.7)  52.3 (15.0)  <.0001 
  
Triglycerides, mg/dl 148.0 (96.1)  111.2 (85.9)  <.0001 
  
Alcohol, ounces/week 3. 4 (4.9)  2.7 (3.8)  <.0001 
  
        
 
 
*HTN: Hypertension. †BMI: Body mass index. ‡HDL: High density lipoprotein. §Std. Dev.: Standard Deviation  
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People with untreated hypertension were younger, more frequently male, and had 
higher blood pressure values than their treated counterparts (Table 14). 
        
 Table 14. Base-line characteristics stratified by hypertension treatment status.  
 
  
  All hypertensive   
  
  Treated hypertensive Untreated hypertensive   
  
Number of subjects (n) 2,763 2,137   
  
  Mean (§Std. Dev.)  Mean (Std. Dev.)  p-value 
  
Age, years 59.5 (9.4)  55.7 (10.3)  <.0001 
  
Male sex, %  50.6 (0.5)  54.1 (0.5)  0.013 
  
Mean *BP, mmHg 98 (11)  107 (8)  <.0001 
  
†BMI, kg/m2 28.7 (5.0)  28.4 (5.2)  0.06 
  
Smoking, % 16.6 (0.4)  22.4 (0.4)  <.0001 
  
‡HDL cholesterol, mg/dl 49.2 (15.5)  50.7 (16.0)  0.001 
  
Triglycerides, mg/dl 149.1 (89.2)  146.7 (104.3)  0.40 
  
Alcohol, ounces/week 3.2 (4.6)  3.7 (5.3)  0.0003 
  
  
 
*BP: Blood pressure. †BMI: Body mass index. ‡HDL: High density lipoprotein. §Std. Dev.: Standard Deviation.   
Mean BP = ([2xdiastolic BP] + systolic BP) / 3. 
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Base-line differences among people treated with different anti-hypertensive drugs 
and the untreated hypertensive group are shown in Table 15. Differences with the 
reference group were nominally significant in regard to age, sex, BMI and smoking 
status. 
    
 Table 15. Base-line characteristics stratified by specific hypertension treatment drug category 
(reference group: untreated hypertensive) 
        
  
Untreated 
hypertensive 
Taking beta-blockers only Taking thiazides only Taking ||ACE-I/ARB only 
Nº of subjects      2,137     676        527       516   
  Mean (§Std Dev) Mean (Std Dev) p-value Mean (Std Dev) p-value Mean (Std Dev) p-value 
Age, years 55.7 (10.3) 60.2 (9.3) <.0001 55.4 (9.4) <.0001 60.6 (8.8) <.0001 
Male sex, % 54.1 (0.5) 59.0 (0.5) 0.0001 42.3 (0.5) <.0001 56.8 (0.5) 0.03 
Mean *BP 107 (8) 98 (12) <.0001 101 (10) 0.04 96(11) <.0001 
†BMI, kg/m2 28.4 (5.2) 28.2 (4.6) 0.03 28.5 (5.2) 0.83 28.7 (4.8) 0.48 
Smoking, % 22.4 (0,42) 16.0 (0,37) 0.02 22.4 (0.4) 0.06 11.0 (0,31) <.0001 
‡HDL  50.7 (16.0) 46.0 (13.3) <.0001 50.3 (16.3) 0.49 49.7 (15.3) 0.86 
Triglycerides 146.7 (104.3) 155.9 (94.6) 0.02 140.9 (73.8) 0.03 143.9 (79.8) 0.23 
Alcohol 3.7 (5.3) 3.4 (5.1) 0.89 3.1 (4.4) 0.15 3.2 (4.3) 0.32 
 
*BP: Blood pressure. Mean BP = ([2xdiastolic BP] + systolic BP)/3, in mmHg. Alcohol: ounces/week. 
†BMI: Body mass index. ‡HDL: High density lipoprotein  cholesterol. HDL and triglycerides, in mg/dl.  
§Std Dev: Standard Deviation.  
Drug exposure groups: subjects treated with more than drug have been excluded.  
NOTE: Uncorrected for multiple testing. Initiation of RAS system agents use started later in time. Thus, caution should be 
exercised when drawing conclusions. 
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4.B. Association of hypertension, hypertension treatment and specific drug 
exposures with change over time in fasting glucose  
  
Versus no hypertension, hypertension was associated with 0.9 mg/dl higher ~4-
year change in fasting glucose (Table 16).  
 
 
Table 16: Association of hypertension with change over time in fasting glucose  
  Age-, sex-adjusted: hypertensive vs. non-hypertensive 
  Hypertension status  
  Yes  No    
Number of subjects (n) (person-exams) 4,492 10,181  
  Mean (*Std. Error) Mean (Std. Error) p-value 
Age, years 57.8 (10.0) 49.3 (10.7) <.0001  
Male sex, % 52.1 (0.5) 43.5 (0.5) <.0001 
 Estimates (Std. Error) Estimates (Std. Error) p-value 
Fasting glucose, mg/dl 96.5 (0.1) 93.0 (0.1) <.0001 
Change in fasting glucose, mg/dl 2.6 (0.2) 1.7 (0.1) <.0001 
 
 
Fasting glucose and change in fasting glucose are mean values across all exams.  
Change in fasting glucose was additionally adjusted for base-line fasting glucose at the beginning of each time period.  
Subjects who started anti-diabetic treatment during a given time period were excluded from the fasting glucose analysis .  
*Std Error: standard error. 
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Versus untreated hypertension, overall treated hypertension conferred 0.4 mg/dl 
higher change in fasting glucose, what might suggest that treating hypertension without 
even accounting for specific drug exposures, further increases change over time in fasting 
glucose (Table 17).  
 
 
Table 17: Association of hypertension treatment with change over time in fasting glucose. 
  Age-, sex-adjusted: treated vs. untreated hypertensive 
  All hypertensive   
  Treated hypertensive Untreated hypertensive   
Number of subjects (n) (person-exams) 2,517 1,985   
  Mean (Std. Error) Mean (Std. Error) p-value 
Age, years 59.5 (9.4) 55.7 (10.3) <.0001 
Male sex, % 50.6 (0.5) 54.1 (0.5) 0.013 
 Estimates (Std. Error) Estimates (Std. Error) p-value 
Fasting glucose, mg/dl 98.4 (0.2) 96.7 (0.2) <.0001 
Change in fasting glucose, mg/dl 3.4 (0.3) 3.0 (0.3) <.0001 
 
Fasting glucose and change in fasting glucose are mean values across all exams.  
Change in fasting glucose was additionally adjusted for base-line fasting glucose at the beginning of each time period.  
Subjects who started anti-diabetic treatment during a given time period were excluded from the fasting glucose analysis .  
*Std Error: standard error. 
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Versus untreated hypertension, RAS agents and combination treatment were 
associated with a higher absolute ~4-year change in fasting glucose, whereas beta-
blockers, thiazides and “others” were not (Tables 18A, 18B, 18C, 18D, 18E).  
 
Table 18A: Association of beta-blockers exposure with change over time in fasting glucose. 
  Age-, sex-, fasting glucose-adjusted models  
  Untreated hypertension   Beta-blockers only 
Number of subjects (person-exams) 1,985 618  
  Mean (Standard error) Mean (Standard error) p-value 
Age, years 55.7 (10.3) 60.2 (9.2) <.0001 
Male sex,% 54.1 (0.5) 59.0 (0.5) 0.0001 
 Estimates (†Std. Error) Estimates (Std. Error) p-value 
Fasting glucose, mg/dl 96.7 (0.2) 98.8 (0.4) <.0001 
Change in fasting glucose, mg/dl 2.8 (0.3) 3.4 (0.5) 0.351 
†Std. error: Standard error. 
 
Table 18B: Association of thiazides exposure with change over time in fasting glucose. 
  Age-, sex-, fasting glucose-adjusted models  
  Untreated hypertension      Thiazides only 
Number of subjects (person-exams) 1,985 495  
  Mean (Standard error) Mean (Standard error) p-value 
Age, years 55.7 (10.3) 55.4 (9.4) <.0001 
Male sex,% 54.1 (0.5) 42.3 (0.5) <.0001 
 Estimates (†Std. Error) Estimates (Std. Error) p-value 
Fasting glucose, mg/dl 96.7 (0.2) 98.0 (0.4) 0.008 
Change in fasting glucose, mg/dl 2.8 (0.3) 2.0 (0.6) 0.237 
†Std. error: Standard error. 
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Table 18C, D and E: Association of ACE-inhibitors/ARB, “combination” and “other” exposures with 
change over time in fasting glucose (†Std. error: Standard error). 
  Age-, sex-, fasting glucose-adjusted models  
  Untreated hypertension   ACE-I / ARB only 
Number of subjects (person-exams) 1,985 457   
  Mean (Standard error) Mean (Standard error) p-value 
Age, years 55.7 (10.3) 60.5 (8.8) <.0001 
Male sex,% 54.1 (0.5) 56.8 (0.5) 0.025 
 Estimates (†Std. Error) Estimates (Std. Error) p-value 
Fasting glucose, mg/dl 96.7 (0.2) 96.5 (0.5) 0.633 
Change in fasting glucose, mg/dl 2.8 (0.3) 4.2 (0.6) 0.037 
  Untreated hypertension   “Combination” 
Number of subjects (person-exams) 1,985 448   
  Mean (Standard error) Mean (Standard error) p-value 
Age, years 55.7 (10.3) 60.0 (9.4) <.0001 
Male sex,% 54.1 (0.5) 47.3 (0.5) 0.023 
 Estimates (†Std. Error) Estimates (Std. Error) p-value 
Fasting glucose, mg/dl 96.7 (0.2) 100.5 (0.5) <.0001 
Change in fasting glucose, mg/dl 2.8 (0.3) 4.2 (0.6) 0.046 
  Untreated hypertension          “Others” 
Number of subjects (person-exams) 1,985 499   
  Mean (Standard error) Mean (Standard error) p-value 
Age, years 55.7 (10.3) 60.9 (9.0) <.0001 
Male sex,% 54.1 (0.5) 45.1 (0.5) 0.0005 
 Estimates (†Std. Error) Estimates (Std. Error) p-value 
Fasting glucose, mg/dl 96.7 (0.2) 98.4 (0.4) 0.0008 
Change in fasting glucose, mg/dl 2.8 (0.3) 4.0 (0.6) 0.06 
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4.C. Association of hypertension, hypertension treatment and specific drug 
exposures with T2DM risk.  
Versus no hypertension, hypertension was significantly associated with ~3-fold 
increased odds of T2DM (OR=2.9; 95% CI 2.8-3.0) (Table 19).  
Table 19: Association of hypertension with estimated incident risk of T2DM 
  Age-, sex-adjusted: hypertensive vs. non-hypertensive 
  Hypertension status  
  Yes  No    
Number of subjects (n) (person-exams) 4,900 10,952  
  Mean (Standard error) Mean (Standard error) p-value 
Age, years 57.8 (10.0) 49.3 (10.7) <.0001  
Male sex, % 52.1 (0.5) 43.5 (0.5) <.0001 
Incidence of diabetes model, % 3.6%  (1.5%) 1.2%  (0.5%) <.0001 
Note: Subjects who started anti-diabetic treatment during a period were excluded from the fasting glucose 
analysis, so numbers of subjects for the fasting glucose analyses were lower than for T2DM. 
 
Versus untreated hypertension, treated hypertension significantly conferred 40% 
increased odds of T2DM (OR=1.4; 95% CI 1.3-1.5) (Table 20).  
Table 20: Association of hypertension treatment with estimated incident risk of T2DM 
  Age-, sex-adjusted: treated vs. untreated hypertensive 
  All hypertensive   
  Treated hypertensive Untreated hypertensive   
Number of subjects (n) (person-exams) 2,763 2,137   
  Mean (Standard error) Mean (Standard error) p-value 
Age, years 59.5 (9.4) 55.7 (10.3) <.0001 
Male sex, % 50.6 (0.5) 54.1 (0.5) 0.013 
Incidence of diabetes model, % 4.9%  (0.7%) 3.6%  (0.5%) 0.023 
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Again, results in Table 20 suggest that treating hypertension without even 
accounting for specific drug exposures, further increases risk of incident T2DM. Versus 
untreated HTN, beta-blockers (OR=1.6; 95% CI 1.1-2.4) (Table 3), combination 
treatment (OR=1.6; 95% CI 1.1-2.5) and others (OR=2.0; 95% CI 1.4-2.9) were 
associated with increased odds of T2DM, unlike thiazides or ACE-inhibitors / ARB.  
 
Table 21A: Association of beta-blockers exposure with estimated risk of incident T2DM. 
  Age-, sex-adjusted. 
  Untreated hypertension    Beta-blockers only 
Number of subjects (person-exams) 2,137 676   
  Mean (Standard error) Mean (Standard error) p-value 
Age, years 55.7 (10.3) 60.2 (9.2) <.0001 
Male sex,% 54.1 (0.5) 59.0 (0.5) 0.0001 
Incidence of diabetes (%) 4.1% 6.6%  0.010 
Odds Ratio, vs. untreated hypertension  NA 1.6  
 
Table 21B: Association of thiazides exposure with estimated risk of incident T2DM. 
  Age-, sex-adjusted. 
  Untreated hypertension    Thiazides only 
Number of subjects (person-exams) 2,137 527   
  Mean (Standard error) Mean (Standard error) p-value 
Age, years 55.7 (10.3) 55.4 (9.4) <.0001 
Male sex,% 54.1 (0.5) 42.3 (0.5) <.0001 
Incidence of diabetes (%) 4.1% 5.8%  0.205 
Odds Ratio, vs. untreated hypertension  NA 1.3  
Table 21C: Association of ACE-inhibitors / ARB exposure with estimated risk of incident T2DM. 
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  Age-, sex-adjusted. 
  Untreated hypertension    ACE-inhibitors/ARB only 
Number of subjects (person-exams) 2,137 516   
  Mean (Standard error) Mean (Standard error) p-value 
Age, years 55.7 (10.3) 60.5 (8.8) <.0001 
Male sex,% 54.1 (0.5) 56.8 (0.5) 0.025 
Incidence of diabetes (%) 4.1% 5.7%  0.239 
Odds Ratio, vs. untreated hypertension  NA 1.3  
Table 21D: Association of “combination” exposure with estimated risk of incident T2DM. 
  Age-, sex-adjusted. 
  Untreated hypertension    “Combination” only 
Number of subjects (person-exams) 2,137 499   
  Mean (Standard error) Mean (Standard error) p-value 
Age, years 55.7 (10.3) 60.0 (9.4) <.0001 
Male sex,% 54.1 (0.5) 47.3 (0.5) 0.023 
Incidence of diabetes (%) 4.1% 6.3%  0.019 
Odds Ratio, vs. untreated hypertension  NA 1.6  
Table 21E: Association of “others” exposure with estimated risk of incident T2DM. 
  Age-, sex-adjusted. 
  Untreated hypertension   “Others” only 
Number of subjects (person-exams) 2,137 545   
  Mean (Standard error) Mean (Standard error) p-value 
Age, years 55.7 (10.3) 60.9 (9.0) <.0001 
Male sex,% 54.1 (0.5) 45.1 (0.5) 0.0005 
Incidence of diabetes (%) 4.1% 7.8%  0.0003 
Odds Ratio, vs. untreated hypertension  NA 2.0  
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4.D. Association of the additive genetic scores with change over time in fasting 
glucose or risk of T2DM  
The effects of individual SNPs upon fasting glucose in the Framingham Offspring Study 
were mostly in the same direction as in GWAS and of expected effect sizes (Table 22).  
Table 22. Fasting glucose-associated SNPs thought to act via beta cell biology, and their per allele 
increase in fasting glucose (FG) according to published and Framingham  Offspring Study data.  
 
SNP *Chr Position Closest gene 
†T2DM 
locus 
Risk 
allele 
Published beta 
effects, mg/dl 
(Standard Error) 
FG-adjusted 
beta effects in 
Framingham  
p value 
rs340874 1 212225879 PROX1 YES C 0.23 (0.05) 0.32 0.02 
rs560887 2 169471394 G6PC2 No C 1.35 ( 0.05) 0.28 0.05 
rs780094 2 27594741 GCKR YES C 0.52 (0.05) 0.35 0.004 
rs11708067 3 124548468 ADCY5 YES A 0.49 (0.05) 0.35 0.03 
rs11920090 3 172200215 SLC2A2 No T 0.36 (0.07) 0.23 0.17 
rs2191349 7 15030834 DGKB/TMEM195 YES T 0.54 (0.05) 0.05 0.70 
rs4607517 7 44202193 GCK YES A 1.12 (0.07) 0.48 0.003 
rs13266634 8 118253964 SLC30A8 YES C 0.49 (0.07) 0.20 0.41 
rs7034200 9 4279050 GLIS3 No A 0.32 (0.05) 0.13 0.29 
rs10885122 10 113032083 ADRA2A No G 0.40 (0.07) 0.30 0.18 
rs7903146 10 114748339 TCF7L2 YES T 0.41 (0.07) 0.52 0.001 
rs11605924 11 45829667 CRY2 No A 0.27 (0.05) -0.02 0.89 
rs174550 11 61328054 FADS1 No T 0.31 (0.05) -0.12 0.40 
rs7944584 11 47292896 MADD No A 0.38 (0.05) 0.003 0.98 
rs10830963 11 92348358 MTNR1B YES G 1.21 (0.05) 0.55 0.001 
rs11071657 15 60221254 FAM148B/C2CD4B No A 0.14 (0.05) 0.11 0.48 
 
The model was adjusted for base-line fasting glucose at each time period. *Chr: Chromosome. 
†T2DM locus: if "YES", overlapping SNP for T2DM. Published beta effects expressed in mg/dl: Based on Dupuis 
et al. (89). They represent the increase of the trait in mg/dl per risk allele. FG-adjusted beta effects in Framingham 
= the increase of the trait in mg/dl per risk allele in our data with FG adjustment only. 
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The effects of individual SNPs upon T2DM in the Framingham Offspring Study 
were mostly in the same direction as in the original GWAS and of expected effect sizes, 
too (Table 23).  
 
Table 23. T2DM-associated SNPs thought to act via beta cell biology, and their per allele increase in 
odds of incident T2DM according to published and Framingham Offspring Study data.  
Analysis in the whole sample of participants (n=15,852 person-exams). 
 
SNP *Chr Position Closest gene 
†FG 
locus 
Risk 
allele 
Published 
‡ORs 
T2DM 
Framingham ORs 
p value 
rs10923931 1 120319482 NOTCH2 No T 1.14 1.03 0.79 
rs340874 1 212225879 PROX1 YES C 1.07 1.16 0.08 
rs243021 2 60438323 BCL11A No A 1.08 1.09 0.23 
rs7578597 2 43586327 THADA No T 1.15 1.22 0.12 
rs780094 2 27594741 GCKR YES C 1.06 1.20 0.01 
rs7593730 2 160879700 RBMS1/ITGB6 No C 1.11 1.14 0.12 
rs1470579 3 187011774 IGF2BP2 No C 1.14 1.03 0.68 
rs11708067 3 124548468 ADCY5 YES A 1.12 1.17 0.10 
rs10010131 4 6343816 WFS1 No G 1.11 0.96 0.54 
rs4457053 5 76460705 ZBED3 No G 1.08 0.96 0.65 
rs7754840 6 20769229 CDKAL1 No C 1.18 1.05 0.51 
rs9472138 6 43919740 VEGFA No T 1.06 1.16 0.06 
rs864745 7 28147081 JAZF1 No T 1.20 0.89 0.08 
rs2191349 7 15030834 DGKB/TMEM195 YES T 1.06 1.14 0.07 
rs4607517 7 44202193 GCK YES A 1.07 1.05 0.55 
rs13266634 8 118253964 SLC30A8 YES C 1.15 0.97 0.85 
rs896854 8 96029687 TP53INP1 No T 1.06 0.97 0.68 
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rs10811661 9 22124094 CDKN2A/2B No T 1.19 1.37 0.002 
rs13292136 9 81141948 TLE4/CHCHD9 No C 1.11 1.25 0.20 
rs12779790 10 12368016 CDC123, CAMK1D No G 1.09 1.02 0.85 
rs1111875 10 60221254 HHEX No C 1.17 1.07 0.33 
rs7903146 10 114748339 TCF7L2 YES T 1.40 1.32 0.0001 
rs5215 11 17365206 KCNJ11 No C 1.09 1.06 0.45 
rs231362 11 2648047 KCNQ1 No G 1.08 0.98 0.77 
rs10830963 11 92348358 MTNR1B YES G 1.13 1.24 0.02 
rs1552224 11 72110746 CENTD2 No A 1.14 0.98 0.85 
rs2334499 11 1653425 HCCA2 No T 1.35 1.10 0.24 
rs1153188 12 53385263 DCD No A 1.08 0.92 0.29 
rs7961581 12 69949369 TSPAN8, LGR5 No C 1.11 1.02 0.84 
rs7957197 12 119945069 OASL/TCF1(HNF1A) No T 1.07 1.12 0.23 
rs11634397 15 78219277 ZFAND6 No G 1.06 1.05 0.1 
rs8042680 15 89322341 PRC1 No A 1.07 1.06 0.46 
rs757210 17 33170628 HNF1B No T 1.12 0.94 0.72 
 
 
*Chr: Chromosome. †FG (fasting glucose) locus: if "YES", overlapping SNP for the fasting glucose analysis.   
‡OR: Odds Ratio. Published ORs: Based on Voight et al. (90). T2DM OR represents the OR of incident T2DM 
for every SNP individually in our data with no further adjustments in the model.  
 
 
Per-weighted genetic score risk allele, change in fasting glucose significantly 
increased by 0.55 mg/dl per risk allele (P=8.9x10-16) in the age-, sex-, fasting glucose-
adjusted models (Table 24).  
 
 
110 
 
 
 
Table 24: Effect of each weighted fasting glucose risk allele on change over time in fasting glucose 
Age-, sex-, fasting glucose-adjusted 
Change in fasting glucose, in mg/dl 
 
 
Estimate p-value 
Age, years 0.2064 <.0001 
Sex, % male 1.7059 <.0001 
Fasting Glucose, mg/dl -0.3503 <.0001 
Fasting glucose 16-SNP Genetic Risk Score 0.5488 8.88178E-16 
 
 
Per-weighted genetic score risk allele, odds of T2DM increased 16.6% (95% CI 
10.0-23.6) per risk allele. Individuals who developed diabetes showed significantly 
higher mean genetic scores than those who did not (17.3 vs. 16.8; p=2.1x10-7) (Table 
25). 
 
Table 25: Mean weighted genetic risk scores in subjects who developed T2DM vs. subjects who did 
not, and additional estimated risk of incident T2DM per weighted risk allele. 
Age-, sex-adjusted model 
T2DM No T2DM 
  
Mean *Std. Dev Mean Std. Dev †OR p-value 
Number of Subjects 422 15,430 
  
Age, years 57.87 9.57 51.78 11.18 1.053 <.0001 
Sex, % male 54.7% 45.9% 1.460 0.0002 
Mean (CI) T2D 33-SNP 
Genetic Risk Score 
17.25 1.73 16.84 1.71 1.166 2.08E-07 
 
*Std. Dev: Standard Deviation.  †OR: Odds ratio, per risk-allele.   
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4.E. Interaction effect between hypertension or its treatment categories and the 
genetic scores to predict change over time in fasting glucose or incident T2DM 
 All interaction P values in joint models including interaction terms for 
hypertension, hypertension treatment or specific antihypertensive drug exposures by 
genetic scores (in bold), predicting change in fasting glucose or T2DM, were non-
significant (all p>0.3) (Tables 26-28).  
 
Table 26. Interaction effect by fasting glucose- or T2DM-genetic risk scores on hypertension for 
change over time in fasting glucose or incident T2DM risk. 
 
Age-, sex-adjusted models, with additional baseline fasting glucose levels -adjustment for change over time 
in fasting glucose. Subjects who started anti-diabetic treatment during a given time period were excluded 
from the change in fasting glucose analyses . 
*Beta effect represents the mg/dl increase in fasting glucose levels per unit increase in the covariate. 
†OR: Odds ratio. GEE: generalized estimating equations. 
 
 
 Change in fasting glucose T2DM 
 *Beta, per mg/dl p-value †OR (GEE) p-value 
Number of subjects  14,683 15,852 (422 diabetes cases) 
Age, years 0.18 <.0001 1.03 <0.0001 
Sex, male 1.60 <.0001 1.34 0.004 
Fasting glucose, mg/dl -0.36 <.0001   
Hypertension (HTN) 1.25 0.35 4.76 0.14 
Mean fasting glucose / T2DM genetic score 0.54 3.2x10
-11
 1.19 0.0004 
HTN x Mean fasting glucose / T2DM genetic score 0.10 0.53 0.98 0.70 
112 
 
 
 
 
 
 
 
 
 
Table 27. Interaction effect by fasting glucose- or T2DM-genetic risk scores on hypertension 
treatment for change over time in fasting glucose or incident T2DM risk. 
 
Age-, sex-adjusted models, with additional baseline fasting glucose levels -adjustment for change over time 
in fasting glucose. Subjects who started anti-diabetic treatment during a given time period were excluded 
from the change in fasting glucose analyses. 
*Beta effect represents the mg/dl increase in fasting glucose levels per unit increase in the covariate. 
†OR: Odds ratio. GEE: generalized estimating equations. ‡FG: fasting glucose. 
 
 
 
 
 
 
 
 
 
 
 
 Change in fasting glucose T2DM 
 *Beta, per mg/dl p-value †OR (GEE) p-value 
Number of subjects  4,502 4,900 (272 diabetes cases) 
Age, years 0.09 <.0001 1.01 0.06 
Sex, male 0.70 0.07 1.22 0.11 
Fasting glucose, mg/dl -0.22 0.0002   
Treated hypertensive  1.69 0.46 1.18 0.90 
Mean fasting glucose / T2DM genetic score 0.52 0.01 1.14 0.038 
HTN Treated x Mean  ‡FG / T2DM genetic score -0.11 0.67 1.02 0.83 
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Table 28. Interaction effect by fasting glucose- or T2DM-genetic risk scores on hypertension specific 
drug exposures for change over time in fasting glucose or incident T2DM risk. 
 
 Change in fasting glucose    T2DM  
 *Beta, per mg/dl p-value †OR (GEE) p-value 
Number of subjects  4,502 4,900 (272 diabetes cases) 
Age, years 0.08 <.0001 1.01 0.10 
Sex, male 0.63 0.10 1.23 0.10 
Fasting glucose, mg/dl -0.22 <.0001   
Mean fasting glucose / T2DM genetic score 0.52 0.004 1.14 0.038 
Hypertensive exposed to beta-blockers only‡ 1.01 0.,77 2.80 0.58 
Beta-blockers x Mean fasting glucose / T2DM genetic score -0.05 0.91 0.97 0.76 
Hypertensive exposed to thiazides only‡ -1.30 0.74 0.26 0.56 
Thiazides x Mean fasting glucose / T2DM genetic score 0.06 0.90 1.10 0.48 
Hypertensive exposed to ACE-I/ARB only‡ 2.39 0.57 2.47 0.69 
ACE-I/ARB x Mean fasting glucose / T2DM genetic score -0.11 0.82 0.96 0.77 
 
Age-, sex-adjusted models, with additional baseline fasting glucose levels -adjustment for change over time 
in fasting glucose. Subjects who started anti-diabetic treatment during a given time period were excluded 
from the change in fasting glucose analyses. 
*Beta effect represents the mg/dl increase in fasting glucose levels per unit increase in the covariate. 
†OR: Odds ratio. GEE: generalized estimating equations. 
‡Specific drug exposures compared to the reference untreated hypertensive group. ACE-I: Angiotensin 
converting enzyme inhibitors. ARB: angiotensin receptor blockers. Data for “combination” and “others” 
not shown.  
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4.F. Joint models including hypertension, its treatments and genetic scores without 
interaction terms to predict change over time in fasting glucose or incident T2DM 
In joint models without interaction, hypertension, thiazides and renin-angiotensin 
agents, and per fasting glucose-SNP risk allele independently predicted change over time 
in fasting glucose (Tables 29 and 30). However, neither hypertension treatment nor beta-
blockers predicted change over time in fasting glucose.  
 
Table 29. Joint models including hypertension or hypertension treatment and the genetic risk scores 
upon change over time in fasting glucose without interaction terms.  
 Change in fasting glucose 
Joint model: hypertension, genetic score;  
age-, sex-, fasting glucose-adjusted model 
*Beta per mg/dl p-value 
Number of subjects  14,683 
Age, years 0.18 <.0001 
Sex, male 1.60 <.0001 
Fasting glucose, mg/dl -0.36 <.0001 
Hypertension 2.10 <.0001 
Mean fasting glucose 16-SNP genetic score 0.57 <.0001 
   
  
Joint model: hypertension treatment, genetic score;  
age-, sex-, fasting glucose-adjusted model 
*Beta per mg/dl p-value 
Number of subjects  4,502 
Age, years 0.09 <.0001 
Sex, male 0.70 0.07 
Fasting glucose, mg/dl -0.22 <.0001 
Treated hypertensive  0.72 0.07 
Mean fasting glucose 16-SNP genetic score 0.45 0.0008 
   
 
We show change in fasting glucose in mg/dl by each unit increase in the covariates  (*betas).  
Subjects who started antidiabetic treatment during a given time period have been excluded from the fasting 
glucose analysis .  
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Table 30. Joint models including specific antihypertensive drug exposures  and the genetic risk scores 
upon change over time in fasting glucose without interaction terms.  
 Change in fasting glucose 
Joint model: specific drug, genetic score;  
age-, sex-, fasting glucose-adjusted model *Beta per mg/dl p-value 
Number of subjects  4,502 
  
Age, years 0.09 <.0001 
Sex, male 0.67 0.08 
Fasting glucose, mg/dl -0.21 <.0001 
Hypertensive exposed to beta-blockers only† 0.17 0.75 
Mean fasting glucose 16-SNP genetic score 0.44 0.0009 
      
Age, years 0.09 <.0001 
Sex, male 0.60 0.12 
Fasting Glucose, mg/dl -0.21 <.0001 
Hypertensive exposed to thiazides only† -1.34 0.02 
Mean fasting glucose 16-SNP genetic score 0.45 0.0008 
      
Age, years 0.09 <.0001 
Sex, %male 0.64 0.09 
Fasting Glucose, mg/dl -0.21 <.0001 
Hypertensive exposed to ‡ACE-I/ARB only† 1.11 0.03 
Mean fasting glucose 16-SNP genetic score 0.45 0.0008 
 
We show change in fasting glucose in mg/dl by each unit increase in the covariates  (*betas). 
Subjects who started antidiabetic treatment during a given time period have been excluded from the fasting 
glucose analysis. 
†Specific drug exposures compared to the reference untreated hypertensive group. ACE-I: Angiotensin 
converting enzyme inhibitors. ARB: angiotensin receptor blockers. Data for “combination” and “others” 
not shown. 
 
 
In joint models without interaction, hypertension, hypertension treatment, and 
T2DM-genetic scores all independently predicted incident T2DM (Table 31). No specific 
hypertension drug predicted incident T2DM in joint models without interaction terms (all 
p values >0.19). 
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Table 31. Joint models including hypertension, hypertension treatment or specific drug exposure 
categories and the genetic scores upon T2DM without interaction terms.  
 
 T2DM 
Joint model: hypertension, genetic score; age-, sex-adjusted model *OR  p-value 
Number of subjects  15,852 (422 diabetes cases) 
Age, years 1.03 <0.0001 
Sex, male 1.34 0.004 
Hypertension 3.16 <.0001 
Mean T2DM 33-SNP genetic score 1.17 1.2x10
-7
 
   
Joint model: hypertension treatment, genetic score; age-, sex-adjusted model *OR  p-value 
Number of subjects  4,900 (272 diabetes cases) 
Age, years 1.01 0.06 
Sex, male 1.22 0.11 
Treated hypertensive  1.57 0.0004 
Mean T2DM 33-SNP genetic score 1.15 0.0002 
   
Joint model: specific drug, genetic score; age-, sex-adjusted model *OR  p-value 
Number of subjects  4,900 (272 diabetes cases) 
Age, years 1.02 0.02 
Sex, male 1.20 0.14 
Hypertensive exposed to beta-blockers only† 1.25 0.19 
Mean T2DM 33-SNP genetic score 1.15 0.0002 
      
Age, years 1.02 0.01 
Sex, male 1.22 0.11 
Hypertensive exposed to thiazides only† 1.03 0.9 
Mean T2DM 33-SNP genetic score 1.15 0.0001 
      
Age, years 1.02 0.01 
Sex, male 1.22 0.11 
Hypertensive exposed to ‡ACE-I/ARB only† 0.96 0.84 
Mean T2DM 33-SNP genetic score 1.15 0.0001 
*OR: Odds ratio, the effect on the odds of incident T2DM by each unit increase in each covariate. 
†People exposed to each specific antihypertensive drug vs. reference untreated hypertensive group. ACE-I: 
Angiotensin converting enzyme inhibitors. ARB: angiotensin receptor blockers. Data for “combination”  
and “others” not shown. 
117 
 
4.G. Secondary analyses 
In secondary analyses using models with further adjustment for a full set of 
possible confounding T2DM risk factors (age, sex, mean blood pressure, body mass 
index, smoking, high density lipoprotein cholesterol, triglycerides levels, alcohol 
consumption, with additional adjustment for fasting glucose levels in the change in 
fasting glucose analyses), the statistically significant results seen in the age-, sex-adjusted 
models were mostly reproduced (Appendices 3-9).  
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5. DISCUSSION 
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5.A. Summary of findings. Putting them in the context of previous knowledge  
5A.1. Results for the hypertension, hypertension categories and genetic 
scores exposures.  
Preliminarily, it should be noted that the Framingham Offspring Study was started 
up recruiting subjects who were 35.5 years on average at exam 1 (data not shown). Thus, 
new onset diabetes rate, number of incident cardiovascular events and number of 
coexisting conditions were low till the latest stages of follow-up. We decided to exclude 
diabetes cases at the beginning of each time period to give more robustness to our 
“pooled” logistic method; we were aware of the possibility of losing statistical power for 
the change over time in fasting glucose analyses, since diabetic patients may be more 
vulnerable to hyperglycemic effects attributable to antihypertensive drugs; however, we 
might have had to deal with the issue of antidiabetic drugs and their confounding effects 
on the results of the fasting glucose analyses. 
We found that hypertension and overall hypertension treatment conferred higher 
~4-year change over time in plasma fasting glucose and risk of incident T2DM in non-
diabetic subjects in the Framingham Offspring Study. Previous work had shown positive 
associations of hypertension with higher fasting glucose and T2DM risk (37). These 
associations had been reported to be stronger in European-ancestry Americans, such as 
Framingham Study’s participants, whereas in African Americans additional risk factors 
apparently confounded the associations (19). Additionally, several studies had also 
demonstrated that genetic variation predicted the individual systolic blood pressure 
response to antihypertensive drugs (143). 
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It is worth to mention that treated hypertension appeared to confer higher change 
over time in plasma fasting glucose and risk of T2DM despite the lower blood pressure 
values found in people receiving medication to treat high blood pressure. This may 
suggest that overall hypertension treatment exerts deleterious effects on glycemic traits.  
The pattern of historical use of antihypertensive drugs reflects the lack of 
availability of more recently discovered drugs in the early stages of follow-up. 
Appearance of RAS agents initially meant lower prescription rates of thiazides and beta-
blockers, but participants went on being prescribed these drugs along time as 
hypertension became more severe.  
Renin-angiotensin system agents were nominally associated with change over 
time in plasma fasting glucose. This finding came as a surprise, since in the literature 
they have been proposed to be neutral or even have a protective effect in regard to T2DM 
incidence. Moreover, in our study they conferred a non-significant 30% higher risk of 
incident T2DM than in the untreated hypertensive group. This may have simply reflected 
confounding by indication, as physicians may have preferentially prescribed RAS agents 
more frequently due to physician-perceived higher risks of diabetes in some of the 
patients.  
Also, we must underscore that we calculated change over time in plasma fasting 
glucose as the absolute difference between fasting glucose levels at the end of the time-
period minus at the beginning, a higher “absolute” difference may have just reflected 
higher “volatility around the line”, as shown in Figure 9; that is, many people with 
significant changes in fasting glucose levels, yet some people with final increased values, 
whereas others with actually decreased values. In fact, average final fasting glucose 
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values in people treated with RAS agents did not differ from those found in the reference 
untreated hypertensive group.  
Figure 9. Representation of final fasting glucose levels (blue horizontal lines) and change over time in 
fasting glucose (red lines), in mg/dl.  
 
The increased change in fasting glucose is statistically significant for RAS agents (data for “combination” 
and “others” not shown). 
 
Exposure to beta-blockers increased ~4-year T2DM risk in the Framingham 
participants, replicating previous findings in the literature (37), though this association 
should be interpreted with caution, as the lower boundary of the 95% CI for the beta-
blockers’ OR includes the ORs for thiazides and RAS agents, which are non-significantly 
associated with T2DM risk. Confounding by indication is usually not an issue for beta-
blockers, as physicians tend to avoid them at a higher perceived risk of diabetes. The 
significant association between beta-blockers exposure and T2DM risk was still 
significant even after accounting for the full set of diabetes risk factor (Appendix 6A). 
Anyway, the possible increased T2DM risk must be weighed against the proven 
cardiovascular benefits of this class of drugs. 
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Thiazides have shown significant associations with T2DM risk in old papers, but 
less convincingly than beta-blockers; in the old papers, no adjustment was done for high 
blood pressure, a strong confounder that could explain their association with T2DM risk. 
The lack of association in our study may simply reflect lack of enough statistical power 
to show a true association, though.  
Users of “any combinations” of beta-blockers, thiazides and RAS agents showed 
a higher T2DM risk, as well; this possibility has already been highlighted in the literature, 
specifically when a combination of a beta-blocker plus a thiazide is used, whereas use of 
a RAS agent in combination seems to lower new onset T2DM risk (142). However, both 
the “combination” and “others” exposure groups were too heterogeneous to draw 
definitive conclusions. 
Weighted genetic risk scores derived from fasting glucose- and T2DM-associated 
SNPs conferred higher ~4-year change over time in plasma fasting glucose and risk of 
incident T2DM. These associations remained statistically significant in all the models. 
We opted for evaluating beta-cell influencing loci only to avoid alternative different 
mechanisms that might have obscured any significant associations. The genotyped SNPs 
successfully passed all the standard quality filters. Even though many of the SNPs used 
were actually imputed, quality of imputation was good for the SNPs tested in this work. 
We preferred to use somewhat loose criteria to select the “beta-cell function-related” 
genetic loci, despite the possibility that having included loci with unclear or unproven 
mechanisms leading to change over time in plasma fasting glucose or increased T2DM risk 
may have subtracted power from the study. As an example, we decided to include GCKR, 
formerly thought to act mainly through liver-mediated insulin resistance, because a recent 
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report suggested possible mechanisms influencing beta-cell function, still to be confirmed 
(144). 
5A.2. Results for the joint models including hypertension or hypertension 
categories and beta-cell common genetic variation. 
As our main result, we detected no interaction effect for any hypertension-treatment 
category-by-genetic risk score. This means that hypertension or antihypertensive specific 
treatments, and fasting glucose- or T2DM-associated common genetic variation influencing 
beta-cell function, did not modify each other’s association with change over time in plasma 
fasting glucose or T2DM risk.  
Nevertheless, hypertension and genetic scores were independently associated with 
glycemic outcomes in joint models without including interaction terms, which means that 
main and marginal effects explain all the associations between the environmental factor 
(hypertension and its treatments) and the genetic background, apparently leaving no place 
for eventual interaction effects. 
Albeit others had evaluated the interaction effects between genetic background and 
environmental factors for T2DM incidence, few have focused on the possible modifying 
role of common genetic variation on the effects derived from antihypertensive drugs upon 
glycemic-related traits. To our knowledge, the interaction effect between T2DM-associated 
genetic loci and T2DM risk has mostly been tested for oral antidiabetic drugs, and only 
exceptionally for other kinds of drugs (145).  
The previously described possible crosstalk between insulin and renin-
angiotensin-aldosterone signaling systems (146) and the plausible anti-diabetic 
mechanisms of the ACE inhibitors and the ARB (147) have prompted some researchers 
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to study the interaction effects upon glucose metabolism. Thus, one case-control study of 
497 cases of diabetes has recently reported that the risk of T2DM due to thiazides use 
was not increased among AR1 (angiotensin receptor-1 gene) 1166CC (rs5186) 
homozygous subjects (OR: 0.63; 95% CI: 0.28-1.40); however, homozygous ACE GG 
subjects (rs1799752) and ACE C allele carriers both had an increased risk of T2DM 
associated with thiazides use; this risk was higher for ACE GG subjects (synergy index 
(SI) for the interaction: 1.70 (95% CI: 1.08-2.66)) (148). In another publication from the 
same group, homozygous 1166CC carriers of AR1 (rs5186) who followed treatment with 
ARB had an increased risk of T2DM as compared to 1166A carriers (interaction OR: 5.3; 
95% CI: 1.8-16.1) (149).  
Becker et al. have studied how common genetic variation modifies diabetes onset 
in people treated with calcium-channel blockers (150): calcium-channel blockers users 
with the TT genotype in rs10494366 at NOS1AP had a higher risk of incident T2DM than 
calcium-channel blockers users with the TT genotype (HR 1.78; 95% CI: 1.03-3.03). The 
lower risk was exclusively found in patients treated with calcium-channel blockers. These 
findings were later replicated in another study (151), in which an association between 
rs10494366 in NOS1AP and incident T2DM was observed among white calcium-channel 
blockers users (HR=1.75; 95% CI: 1.08-3.12; p=0.016) for the T allele. Again for 
calcium-channel blockers, Irving et al. more recently reported that SNP rs2228576 
polymorphism, at the amiloride-sensitive epithelial sodium channel SCNN1A locus, 
modified the association between fasting glucose levels and amlodipine vs. chlortalidone 
treatment (p<0.001) (152). 
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According to our results, the influence that hypertension or its treatment exerted 
on change over time in plasma fasting glucose and T2DM risk was homogeneous 
irrespectively of the genetic susceptibility conferred by fasting glucose- or T2DM-
associated common genetic variation. And reciprocally, the effect of fasting glucose- and 
T2DM-associated common genetic variation on change over time in plasma fasting 
glucose and T2DM risk was not greater in the presence of hypertension or hypertension 
treatment.  
Had we found significant interaction effects in our study, the clinical implication 
could have been that, for similar efficacy rates, clinicians might preferentially opt for 
using drugs with less adverse metabolic effects. These adverse effects may be more easily 
anticipated by knowing the genetic susceptibility of the patients and the possible 
modifying effect of hypertension treatment to increase over time their fasting glucose 
levels or make them more prone to develop T2DM.  
Our main hypothesis of seeking interaction effects between fasting glucose- and 
T2DM-associated SNPs and hypertension upon change over time in plasma fasting 
glucose and T2DM risk thus seemed plausible and based on clinical applications. 
Notwithstanding the previous idea, some authors have lately proposed that the therapeutic 
or adverse effects of any pharmacological action on glucose metabolism may not be 
adequately detected by using change over time in plasma fasting glucose or T2DM alone, 
since the interplay of multiple physiologic systems to maintain glycemia in a narrow 
range may blunt the final effects, and perhaps other phenotypes more closely related to 
the action of the drug should be defined and tested (153). 
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5.B. Strengths of our work. 
 Confounding by indication, which is a matter of concern in observational studies of 
drug therapies, has traditionally precluded claiming irrefutable evidence for the effect of 
hypertension and its treatment on glycemic control and risk of incident diabetes. Thus, the 
fact that genetics do not confound by indication (“Mendelian randomization”) gives 
strength to our study.  
The quality of the data from the Framingham studies is outstanding: clinical and 
laboratory data have been thoroughly collected in every exam, and dozens of papers in the 
literature are based on this methodology.  
The pooled analyses gave robustness to our analyses and partly offset the limited 
sample size. Having replicated the results from the age-, sex-adjusted models in the fully-
adjusted models for the whole set of T2DM clinical risk factors gives strength to our results 
and accounts for the possibility of residual confounding. We were able to account for 
correlation effects within individuals and within families, which is an issue in these pooled 
analyses carried out in populations where familial relationships cannot be fully ruled out. 
The specific drug-exposures analyses with mutually-exclusive drug categories 
allowed an orthodox analysis of the true effects found for every medication group.  
 At last, a “clean”, detailed, step-by-step statistical analysis was planned and 
performed for a logical interpretation of the results. 
 
5.C. Limitations of this work. 
Firstly, if we had observed evidence for a gene-environment interaction, its 
biological plausibility should have been further critically discussed and potential 
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confounders or intermediate pathways would need to be explored. We might not have been 
able to confirm or reject conclusions dealing with biological mechanisms by 
epidemiological data alone. Only in light of additional lines of evidence, such as large 
randomized controlled trials and functional experiments, may the inferences toward 
causality be extended (154). Thus, even though the potential clinical relevance or impact of 
a reported gene-environment interaction might have been discussed, potential implications 
should have been evaluated in subsequent studies designed for that special purpose. 
Secondly, some methodological limitations should be further pointed out: we only 
analyzed common genetic variants; eventual incorporation of rare variants with larger 
effects could have further enhanced our ability to detect significant interaction effects by 
constructing more powerfully discriminative genetic scores. Furthermore, genome wide 
association studies SNPs only tag putative functional variants; had we had knowledge of 
the functional variants at each locus, we might have been able to account for a more 
precise genetic effect and detect interaction. Moreover, Framingham Offspring Study 
subjects were mostly white and of European ancestry. Had we analyzed populations with 
a different ancestry, we might have seen different results.  
Additionally, in the Framingham Offspring Study, we were unable to ascertain 
exact exposure duration or a precise date of T2DM onset in the participants, since this 
information was retrieved only at subsequent visits during the scheduled follow-up of the 
participants. However, we used a robust pooled-regression analysis method that 
accounted for this limitation.  
Lastly, we only had power to detect relatively large regression coefficients for the 
interaction effects with our sample size. Greater power might be needed to unmask very 
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subtle interaction effects, and even more to look at specific SNP effects. Although SNP 
level effects might be mechanistically more precise, our sample size prohibited single 
SNP analyses.  
 
5.D. Future directions. 
Trials are under way to explore and identify the genetic determinants of the 
antihypertensive and adverse metabolic responses to antihypertensive drugs: for instance, 
the PEAR Study has been started to evaluate the genetic effects on the response to a 
thiazide diuretic (hydrochlorothiazide), a β-blocker (atenolol), and their combination 
(155).  
Even though we have found no significant interaction effects with models using 
genetic scores, this study hints at the possibility of analyzing individual SNP-by-specific 
drug category interaction tests in larger samples, or by clustering SNPs according to the 
biological pathways through which they reportedly operate. Researchers should next 
design this kind of studies to address whether there is some biological basis for fasting 
glucose impairment or T2DM risk associated with anti-hypertensive therapies. 
Here we describe a potential approach for future studies, using beta-blockers 
exposure as an example: we have shown a higher incident T2DM risk in hypertensive 
people who were exposed to beta-blockers treatment.  As mentioned in the background 
section, potential mechanisms that could explain the association include weight gain, 
attenuation of the beta-receptor–mediated release of insulin from pancreatic beta cells, 
decreased insulin sensitivity or changes in the level of aerobic exercise or subtle changes 
in the cellular actions of insulin (48). 
129 
 
According to the findings from an extensive search in the literature, it is 
reasonable to select the following SNPs, as potential candidates to test the interaction 
effects between individual SNPs and beta-blockers exposure on T2DM risk: 
In chromosome 3, we have tested rs1470579, at IGF2BP2, related to pancreatic 
development and protein binding; according to Groenewoud et al., variants at this genetic 
locus attenuate the first phase of insulin secretion (156). Propranolol has been shown to 
inhibit insulin exocytosis (157). So, it is a plausible hypothesis that propranolol exposure 
might interact with genetic variation at this genetic locus to modify incident T2DM risk. 
In a similar fashion, in chromosome 6, rs7754840, at CDKAL1, which regulates a signal 
transducer and downregulates insulin expression, should also be included in the beta-
blockers analyses, due to the effect of genetic variation at this locus on first-phase insulin 
exocytosis mediated through potassium (ATP) channel responsiveness (158). 
In another recent report, Park et al. argue that propranolol completely abolished 
induction of VEGF expression in cancer cells (159); thus, rs9472138, at VEGFA, which 
regulates a vascular endothelial growth factor, but whose mechanistic link with diabetes 
onset has not been readily explained yet, should also be included in the list of specific 
beta-blockers exposure SNPs.  
In chromosome 7, at DGKB/TMEM195, rs2191349 was included in our T2DM 
analyses. This locus seems to regulate diacylglycerol-kinase mediated insulin secretion; it 
has been reported that, in small arteries, diacylglycerol kinase activity is increased by 
adrenergic stimulation implying a role in vascular smooth muscle responses (160). Then, 
we might also want to include this SNP in our beta-blockers exposure list of SNPs. 
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There is an interesting locus at chromosome 11, KCNQ1, linked to potassium 
channel-mediated insulin release, for which we analyzed rs231362 as a T2DM associated 
SNP. It has been suggested that expanded gene survey may be required in KCNQ1-
related patients who are resistant to beta-blockers therapies in regard to the long QT 
interval syndrome (161). There seems to be a modifying effect on behalf of beta-blocker 
therapies in this disease, as heterogeneity has been described for genetic variation at this 
locus. Lastly, rs10830963, at MTNR1B, in chromosome 11, related to melatonin and 
circadian rhythm, should also be tested for an interaction effect between beta-blockers 
exposure and genetic variation at this locus, since a very recent report underscores the 
relevance of catecholamines to explain the relationship between insulin and melatonin in 
regard to T2DM risk (162).    
This way, we would pick 6 SNPs, for which proposed biological actions could 
somehow interact with beta-blockers exposure in hypertensive patients to confer a 
heterogeneous risk of developing T2DM. And in a similar fashion we might proceed with 
thiazides and RAS agents’ exposures, and also for the change in fasting glucose set of 
analyses.  
It can be argued that these tests are largely exploratory, but it can be replied that 
with this design, in individual SNPs analyses, and also by clustering SNPs in a way that 
accounts for similar biological pathways through which they reportedly operate, 
researchers could attempt to address whether there is some biological basis for fasting 
glucose impairment or T2DM risk associated with anti-hypertensive therapies. 
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Use of larger samples and eventual incorporation of new genetic information with 
rare variants could enhance our ability to detect interaction effects upon glycemia on 
behalf of antihypertensive therapies. In fact, by the time this work was about to be 
printed, an updated list of over 63 SNPs have been associated with T2DM (163), and an 
updated list of 36 SNPs have been associated with fasting glucose levels (164), and these 
numbers are expected to increase due to the synergistic research efforts in the field. 
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6. CONCLUSIONS 
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1. In the Framingham Offspring Study, as people aged, body mass index 
increased and both hypertension and hypertension treatment became more 
prevalent.  
2. Versus no hypertension, hypertension was associated with higher ~4-year 
change in plasma fasting glucose and increased odds of type 2 diabetes.  
3. Versus untreated hypertension, treated hypertension conferred higher ~4-year 
change in plasma fasting glucose and increased odds of type 2 diabetes. 
4. Use of renin-angiotensin system agents was nominally associated with higher 
change over time in plasma fasting glucose. Use of beta-blockers was 
nominally associated with increased odds of type 2 diabetes.  
5. Change over time (~4-year) in plasma fasting glucose and odds of type 2 
diabetes significantly increased per weighted genetic risk score allele.  
6. People who developed type 2 diabetes had higher weighted genetic risk scores 
tan people who did not. 
7. Hypertension and the genetic risk scores (per-fasting glucose-SNP- or per-
type 2 diabetes-weighted genetic risk allele) independently predicted change 
over time (~4-year) in plasma fasting glucose or type 2 diabetes risk. 
8. Hypertension or antihypertensive specific treatments, and fasting glucose- or 
type 2 diabetes-associated common genetic variation influencing beta-cell 
function, did not modify each other’s association with change over time in 
plasma fasting glucose or type 2 diabetes risk.  
9. Therefore, the influence that hypertension or its treatment exerted on change 
over time in plasma fasting glucose or type 2 diabetes risk was homogeneous 
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irrespectively of the genetic susceptibility conferred by fasting glucose- or 
type 2 diabetes-associated common genetic variation.  
10. Reciprocally, the effect of fasting glucose- and type 2 diabetes-associated 
common genetic variation on change over time in plasma fasting glucose or 
type 2 diabetes risk was not greater in the presence of hypertension, treated 
hypertension or hypertension specific treatments.  
11. Additional possible confounding type 2 diabetes risk factors (mean blood 
pressure, body mass index, smoking, high density lipoprotein cholesterol, 
triglycerides levels, and alcohol consumption) did not seem to explain most of 
the statistical associations found in the age-, sex-adjusted models, with further 
adjustment for fasting glucose levels in the change over time in plasma fasting 
glucose analyses.  
12. This study hints at the possibility of analyzing individual SNP-by-specific 
drug category interaction tests in larger population samples, or by clustering 
SNPs according to the biological pathways through which they reportedly 
operate, to address whether there is some biological basis for fasting glucose 
impairment or type 2 diabetes risk associated with anti-hypertensive therapies.  
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7. ABBREVIATIONS AND ACRONYMS 
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2hrG: 2 hour glucose levels 
ACE: angiotensin converting enzyme 
ADA: American Diabetes Association 
ALLHAT: antihypertensive and lipid-lowering treatment to prevent heart attack 
trial 
ANBP-2: Australian national blood pressure-2 
AP: angina pectoris 
AR1: angiotensin receptor 1 
ARB: angiotensin receptor blocker 
ARIC: atherosclerosis risk in communities  
ATP: adenosine triphosphate 
BMI: body mass index 
BP: blood pressure 
BRLMM: bayesian robust linear modeling using Mahalanobis distance 
CAPPP: captopril prevention project 
CCB: calcium channel blocker 
CHARM: candesartan in heart failure assessment of reduction in mortality and 
morbidity 
CI: confidence interval 
DNA: desoxi-ribonucleic acid 
ECG: electrocardiogram 
FG: fasting glucose 
FI: fasting insulin 
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GEE: Generalized Estimating Equations 
GLP-1: glucagon-like peptide 1 
GWAS: genome-wide association scan 
HapMap: haplotype map 
HOMA-IR: homeostasis model assessment of insulin resistance 
HOPE: heart outcomes prevention evaluation 
HR: hazard ratio 
INSIGHT: intervention as a goal in hypertension trial 
Kb: kilobase 
LD: linkage disequilibrium 
LIFE: losartan intervention for endpoint reduction 
MAF: minor allele frequency 
MODY: maturity-onset diabetes of the young 
NAVIGATOR: nateglinide and valsartan in impaired glucose tolerance outcomes 
research 
NHANES: National Health and Nutrition Examination Survey 
NHLBI: National Heart, Lung and Blood Institute 
OGTT: oral glucose tolerance test 
OR: odds ratio 
RAS: renin-angiotensin system 
RR: relative risk 
SHEP: systolic hypertension in the elderly program  
SI: synergy index 
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SNP: single-nucleotide polymorphism 
T2DM: type 2 diabetes mellitus 
USA: United States of America 
VALUE: valsartan anti-hypertensive long-term use evaluation 
WHO: World Health Organization 
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Appendix 1. Variables coding in Framingham. Example: anti-hypertensive drugs 
exposure. 
For exam 1, exposure to anti-hypertensive medication was coded this way: 
       A70           C7/14        History of Hypertension 
                                     0  no   
                                     1  yes   
                                     .  unknown   
  
       A78           C7/22        Diuretics For Blood Pressure  
                                     3  no    
                                     4  yes (now)   
                                     5  yes (not now)   
                                     .  unknown    
      
       A79           C7/23        Hypotensives (excluding diuretics) 
                                     6  no    
                                     7  yes (now)   
                                     8  yes (not now)   
                                     .  unknown     
 
For exam 7, the items that collect information on blood pressure were: 
        G008 
IN THE INTERIM HAVE YOU TAKEN MEDICATION FOR THE TREATMENT  
OF HYPERTENSION? 
 0  NO     
 1  YES     
 2  YES, NOT NOW     
 .  UNKNOWN      
      
        G013 CARDIOVASCULAR MEDICATIONS: CALCIUM CHANNEL BLOCKERS   
 (NIFEDIPINE, VERAPAMIL, DILTIAZEM)    
 0  NO     
 1  YES, NOW     
 2  YES, NOT NOW     
 3  MAYBE     
 .  UNKNOWN      
      
        G017 CARDIOVASCULAR MEDICATIONS: BETA BLOCKERS   
 0  NO     
 1  YES     
 2  YES, NOT NOW     
                         3  MAYBE     
 .  UNKNOWN      
 NOTE:  CHOICE OF "2 YES, NOT NOW" AND   
                       "3 = MAYBE" WAS ADDED DURING EXAM 7     
                        DATA COLLECTION     
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        G018 BETA BLOCKER GROUP     
  0  DOES NOT TAKE BETA BLOCKERS    
 01  PROPRANOLOL     
 02  TIMOLOL     
 03  NADOLOL     
 04  ATENOLOL     
 05  METOPROLOL     
 06  PINDOLOL     
 07  CARVEDILOL     
 08  LABETALOL     
 09  OTHER     
  .  UNKNOWN      
      
        G019 BETA BLOCKER GROUP: DOSE (MG/DAY) OF BETA BLOCKER   
 0  DOES NOT TAKE BETA BLOCKERS    
 3 - 400     
 .  UNKNOWN      
        G020 CARDIOVASCULAR MEDICATIONS: LOOP DIURETICS (LASIX, ETC.) 
 Combined with 
G023 
 0  NO     
 1  YES, NOW     
 2  YES, NOT NOW     
 3  MAYBE     
 .  UNKNOWN      
      
        G022 CARDIOVASCULAR MEDICATIONS: THIAZIDE DIURETICS   
 0  NO     
 1  YES, NOW     
 2  YES, NOT NOW     
 3  MAYBE     
 .  UNKNOWN      
      
        G023 CARDIOVASCULAR MEDICATIONS: K-SPARING DIURETICS   
 0  NO     
 1  YES, NOW     
 2  YES, NOT NOW     
 3  MAYBE     
 .  UNKNOWN      
      
        G024  CARDIOVASCULAR MEDICATIONS: POTASSIUM SUPPLEMENTS   
 0  NO     
 1  YES, NOW     
 2  YES, NOT NOW     
 3  MAYBE     
 .  UNKNOWN      
      
        G025  CARDIOVASCULAR MEDICATIONS: RESERPINE DERIVATIVES   
 0  NO     
 1  YES, NOW     
 2  YES, NOT NOW     
 3  MAYBE     
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 .  UNKNOWN      
      
        G026 CARDIOVASCULAR MEDICATIONS: METHYLDOPA (ALDOMET)   
 0  NO     
 1  YES, NOW     
 2  YES, NOT NOW     
 3  MAYBE     
 .  UNKNOWN      
      
        G027 CARDIOVASCULAR MEDICATIONS: ALPHA-1 AGONIST   
 (CLONIDINE, WYTENSIN, GUANABENZ)    
 0  NO     
 1  YES, NOW     
 2  YES, NOT NOW     
 3  MAYBE     
 .  UNKNOWN      
      
        G028 CARDIOVASCULAR MEDICATIONS: ALPHA-2 BLOCKERS   
 (PRAZOSIN, TERAZOSIN, DOXAZOSIN)    
 0  NO     
 1  YES, NOW     
 2  YES, NOT NOW     
 3  MAYBE     
 .  UNKNOWN      
      
        G029 CARDIOVASCULAR MEDICATIONS: RENIN-ANGIOTENSIN BLOCKING DRUGS  
 0  NO     
 1  YES, NOW     
 2  YES, NOT NOW     
 3  MAYBE     
 .  UNKNOWN      
      
        G031 CARDIOVASCULAR MEDICATIONS: ANGIOTENSIN II ANTAGONISTS   
 0  NO     
 1  YES, NOW     
 2  YES, NOT NOW     
 3  MAYBE     
 .  UNKNOWN      
      
        G030 CARDIOVASCULAR MEDICATIONS: PERIPHERAL VASODILATORS   
 (HYDRALAZINE, MINOXIDIL, ETC.)    
 0  NO     
 1  YES, NOW     
 2  YES, NOT NOW     
 3  MAYBE     
 .  UNKNOWN      
      
        G032 CARDIOVASCULAR MEDICATIONS: OTHER ANTI-HYPERTENSIVES   
 0  NO     
 1  YES, NOW     
 2  YES, NOT NOW     
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 3  MAYBE     
 .  UNKNOWN      
         
       G708 TREATMENT FOR BLOOD PRESSURE    
 0  NO     
 1  YES (BY MEDS AND PHYSICIAN OPINION)   
 .  UNKNOWN      
      
       G711 HYPERTENSION     
 0  NO     
 1 YES  BY ELEVATED BP OR TREATMENT FOR BP   
 
.  UNKNOWN  
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Appendix 2. Coding of outcomes in the Framingham Offspring Study: coronary 
heart disease.  
 
01-09      CHD 
 
              01  MI RECOGNIZED, WITH DIAGNOSTIC ECG 
 
              02  MI RECOGNIZED, WITHOUT DIAGNOSTIC ECG, WITH ENZYMES AND HISTORY 
 
03  MI RECOGNIZED, WITHOUT DIAGNOSTIC ECG, WITHAUTOPSY EVIDENCE, NEW 
EVENT (SEE ALSO CODE 09) 
 
              04  MI UNRECOGNIZED, SILENT 
 
              05  MI UNRECOGNIZED, NOT SILENT 
 
               NOTES on MI: Recognized means at time of MI occurrence, an MI was known to have taken place. 
               Unrecognized means MI was not known to have taken place until later.  Silent MI means at time of MI,  
 there were no symptoms similar to MI symptoms.  Not silent means that symptoms were present. 
 
Unrecognized MIs are dated using the midpoint between the dates of the diagnostic ECGs. Hierarchy for 
coding MI is based on strongest evidence: EVENT=01 > EVENT=02 > EVENT=03. 
 
              06  AP, FIRST EPISODE ONLY 
If date of was unavailable, AP is dated as midpoint of the interval between medical encounters 
(FHS exams, hospitalizations or MD office visits).  If AP occurred with MI or CI, then use same 
date as MI or CI.   
 
  Before 1987, if AP occurred just before MI or CI, then AP date was assigned 3 months before 
  MI or CI. If AP occurred just after MI or CI, then AP date was assigned 3 months after MI or CI.   
 
Beginning in 1987, if approximate or exact date of new angina was available, then that date was 
assigned as date of AP. 
 
              07  CI, DEFINITE BY BOTH HISTORY AND ECG. 
 
              08  QUESTIONABLE MI AT EXAM 1   
Date same date as Exam 1 for Original cohort and Offspring cohort. For the other cohort groups, a 
date other than the Exam 1 date is used if available.  Any questionable MI episode at Exam 1:  
definite MI history without enzymes or autopsy, or possible MI on ECG.  Does not include 
questionable AP. 
 
              09  MI ACUTE AUTOPSY, NOT A NEW EVENT.   
  This is coded when there has been a previously coded MI (1 or 2) and that MI shows on autopsy. 
 
  CHD  Coronary Heart Disease 
     MI   Myocardial Infarction 
    ECG  Electrocardiogram 
     AP   Angina Pectoris 
     CI   Coronary Insufficiency 
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Appendix 3. Blood samples treatment for DNA extraction in Framingham. 
 
In summary, buffy coats of nucleated cells obtained from anti-coagulated blood 
(ACD or EDTA) were re-suspended in 15 ml polypropylene centrifugation tubes with 3 
ml of nuclei lysis buffer. The cell lysates were digested overnight. After digestion was 
complete, 1 ml of saturated NaCl (approximately 6M) was added to each tube and shaken 
vigorously for 15 seconds, followed by centrifugation at 2500 rpm for 15 minutes. The 
precipitated protein pellet was left at the bottom of the tube and the supernatant 
containing the DNA was transferred to another 15 ml polypropylene tube. Exactly 2 
volumes of room temperature absolute ethanol were added and the tubes inverted several 
times until the DNA precipitated. The precipitated DNA strands were removed with a 
plastic spatula or pipette and transferred to a 1.5 ml micro-centrifuge tube containing 
100-200 pi TE buffer. The DNA was allowed to dissolve 2 hours at 37°C before being 
quantified. 
The Mapping 500K Array Set builds on the proven and simple approach for 
reducing genomic complexity that is employed by the GeneChip Human Mapping 10K 
Array and the GeneChip Mapping 100K Set (1). Total genomic DNA (250 ng) is digested 
with a restriction enzyme (Nsp I or Sty I) and ligated to adaptors that recognize the 
cohesive four base-pair overhangs. All fragments resulting from restriction enzyme 
digestion, regardless of size, were substrates for adaptor ligation. A generic primer that 
recognized the adaptor sequence was used to amplify adaptor-ligated DNA fragments. 
Polymerase chain reaction conditions have been optimized to preferentially amplify 
fragments in the 200 to 1,100 base-pair size range. The amplified DNA was then 
fragmented, labeled, and hybridized to a GeneChip Human Mapping 250K Array.  
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All SNPs on the GeneChip Human Mapping 500K Array Set went through a 
rigorous screening and validation process. Optimal SNPs were selected and tiled on 
arrays based on accuracy, call rate, and linkage disequilibrium analysis in three 
populations across the genome. The median physical distance between SNPs was 2.5 
kilo-bases (kb) and the average distance between SNPs was 5.8 kb. The average 
heterozygosity of these SNPs was 0.30. Eighty-five percent of the human genome is 
within 10 kb of a SNP.  
The technology for iPLEX was based on the fact that parent ion masses could be 
easily determined from the spectrum without the need for complex data processing and 
were accessible as numerical data for direct processing (2). The mass spectrometric 
approach enabled direct analyte detection with 100% specificity and needed no 
redundancy (3). This accuracy and efficacy were combined with sample miniaturization, 
bioinformatics, and chip-based technologies for parallel processing of numerous samples 
(4). Using a proprietary algorithm, masses -as well as signal intensities- were 
automatically analyzed and interpreted. After completion of analysis, the results were 
transferred to a database and stored as accessible genetic information. The database also 
provided a tool for visual control and comparison of spectra with theoretically expected 
results (5). 
 
References for methods (blood samples treatment) 
1. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting 
DNA from human nucleated cells. Nucleic Acids Res. 1988; 16:1215. 
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2. Jurinke C, van den Boom D, Cantor CR, Köster H. Automated Genotyping Using 
the DNA MassArray Technology. Methods in Molecular Biology, vol. 170: DNA 
Arrays: Methods and Protocols. Edited by: J. B. Rampal. Humana Press Inc., 
Totowa, NJ. 2008; 170:103-116. 
3. Ross P, Hall L, Smirnov I, Haff L. High level multiplex genotyping by MALDI-
TOF mass spectrometry. Nat Biotech. 1998; 16:1347-1351. 
4. Buetow KH, Edmonson M, MacDonald R, et al. High-throughput development 
and characterization of a genomewide collection of gene-based single nucleotide 
polymorphism markers by chip-based matrix-assisted laser desorption/ionization 
time-of-flight mass spectrometry. Proc Natl Acad Sci. 2001; 98:581-584. 
5. Braun A, Little DP, Reuter D, Muller-Mysock B, Köster H. Improved analysis of 
microsatellites using mass spectrometry. Genomics. 1997; 46:18-23. 
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Appendix 4. Replication of the results shown in Tables 13, 16 and 19 in full T2DM 
risk factors-adjusted models: association of hypertension with change in fasting 
glucose and incident T2DM. 
 
 
 
 
 
HYPERTENS IVE VS. NON-HYPERTENSIVE, fully-adjusted model 
    
  Hypertension status 
    Yes (HTN=1) No (HTN=0) 
Number of Subjects (N) 4,900 10,952 
  Mean Std Dev Mean Std Dev p-value 
Age, years 57.83 9.96 49.31 10.68 <.0001  
Sex, % male 52.12 0.49 43.45 0.50 <.0001  
BMI, kg/m
2
 28.53 5.10 25.94 4.32 <.0001  
Smoking, % 19.11% 0.39 26.85% 0.44 <.0001  
HDL cholesterol, mg/dl 49.83 15.69 52.34 15.03 <.0001 
Triglycerides, mg/dl 148.00 96.10 111.20 85.93 <.0001 
Alcohol, ounces/week 3.38 4.88 2.71 3.83 <.0001 
Number of Subjects (N) 4,445 10,045 
 
Traits Mean Std. Error Mean Std. Error p-value 
Fasting glucose, mg/dl 95.55 0.14 93.42 0.09 <.0001  
FG_adj. change in fasting glucose, mg/dl 2.25 0.18 1.82 0.11 <.0001 
      
Incidence of diabetes  2.81% 3.36% 1.41% 1.86% <.0001 
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Appendix 5. Replication of the results shown in Tables 14, 17 and 20 in full T2DM 
risk factors-adjusted models: association of hypertension treatment with change in 
fasting glucose and incident T2DM. 
 
 
 
 
 
 
 
  
TREATED VS. UNTREATED HYPERTENSIVE, fully-adjusted model 
    
  All hypertensive   
  Treated Hypertensives Untreated Hypertensives   
Number of Subjects (N) 2,763 2,137   
  Mean Std Dev Mean Std Dev p-value 
Age, years 59.46 9.37 55.72 10.30 <.0001 
Sex, % male 50.56 0.50 54.14 0.50 0.013 
Mean BP, mmHg, ([2xDBP]+SBP) / 3 98.39 11.13 107.30 7.52 <.0001 
BMI, kg/m
2
 28.65 4.98 28.37 5.24 0.06 
Smoking, % 16.58 0,37 22.39 0.42 <.0001 
HDL cholesterol, mg/dl 49.17 15.47 50.68 15.93 0.001 
Triglycerides, mg/dl 149.10 89.21 146.70 104.30 0.40 
Alcohol, ounces/week 3.15 4.54 3.68 5.29 0.0003 
Number of Subjects (N) 2,494 1,951 
 
Traits Mean Std. Error Mean Std. Error p-value 
Fasting glucose, mg/dl 98.27 0.19 96.92 0.21 <.0001 
FG_adj. change in fasting glucose, mg/dl 3.24 0.26 3.09 0.30 <.0001 
      Incidence of diabetes  4,94% 3.98% 3,39% 2,90% 0,015 
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Appendix 6. Replication of the results shown in Tables 15, 18 and 21 in full T2DM 
risk factors-adjusted models: association of specific anti-hypertensive drug 
exposures with change in fasting glucose and incident T2DM.  
(*p-values: compared with the untreated hypertensive reference group). 
 
 
 
 
6.A. BETA-BLOCKERS EXPOSURE, fully-adjusted model 
  Untreated hypertensive Taking Beta Blockers ONLY 
Number of Subjects (N) 2,137 676 
  MEAN 
STD 
DEV 
MEAN 
STD 
DEV 
*p-value 
Age, years 55.72 10.3 60.24 9.25 <.0001 
Sex, % male 54.1 0.50 59.0 0.49 0.0001 
Mean BP, mmHg, ([2xDBP]+SBP) / 3 107.30 7.51 97.46 11.47 <.0001 
BMI, kg/m
2
 28.37 5.24 28.17 4.58 0.032 
Smoking, % 22.39 0.42 15.97 0.37 0.018 
HDL cholesterol, mg/dl 50.68 15.93 46.00 13.25 <.0001 
Triglycerides, mg/dl 146.7 104.3 155.90 94.63 0.023 
Alcohol, ounces/week 3.68 5.29 3.41 5.05 0.888 
Number of Subjects (N) 1,951 609 
Traits  
Param 
Estimates 
Std. 
Error 
Param 
Estimates 
Std. 
Error 
p-value 
Fasting glucose, mg/dl 96.93 0.23 98.63 0.39 0.0002 
FG_adj. change in fasting glucose, mg/dl 2.88 0.31 3.17 0.53 0.643 
     
Incidence of diabetes 4.10% 6.64% 0.010 
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6.B. THIAZIDES EXPOSURE, fully-adjusted model 
  Untreated hypertensive Taking Thiazides ONLY 
Number of Subjects (N) 2,137 527 
  MEAN 
STD 
DEV 
MEAN 
STD 
DEV 
*p-value 
Age, years 55.72 10.3 55.43 9.37 <.0001 
Sex, % male 54.1 0.50 42.3 0.50 <.0001 
Mean BP, mmHg, ([2xDBP]+SBP) / 3 107.30 7.51 101.30 10.06 0.036 
BMI, kg/m
2
 28.37 5.24 28.49 5.17 0.835 
Smoking, % 22.39 0.42 22.39 0.42 0.055 
HDL cholesterol, mg/dl 50.68 15.93 50.28 16.34 0.491 
Triglycerides, mg/dl 146.70 104.3 140.90 73.82 0.026 
Alcohol, ounces/week 3.68 5.29 3.12 4.35 0.150 
Number of Subjects (N) 1,951 493 
Traits  
Param 
Estimates 
Std. 
Error 
Param 
Estimates 
Std. 
Error 
p-value 
Fasting glucose, mg/dl 96.93 0.23 98.12 0.42 0.013 
FG_adj. change in fasting glucose, mg/dl 2.88 0.31 2.07 0.57 0.212 
     
Incidence of diabetes 4.10% 5.77% 0.111 
 
6.C. ACE-INHIBITORS/ARB EXPOSURE, fully-adjusted model 
  Untreated hypertensive Taking ACE-I/ARB ONLY 
Number of Subjects (N) 2,137 516 
  MEAN 
STD 
DEV 
MEAN 
STD 
DEV 
*p-value 
Age, years 55.72 10.3 60.55 8.84 <.0001 
Sex, % male 54.1 0.50 56.8 0.49 0.025 
Mean BP, mmHg, ([2xDBP]+SBP) / 3 107.30 7.51 96.40 10.45 <.0001 
BMI, kg/m
2
 28.37 5.24 28.67 4.77 0.479 
Smoking, % 22.39 0.42 10.96 0.31 <.0001 
HDL cholesterol, mg/dl 50.68 15.93 49.71 15.27 0.855 
Triglycerides, mg/dl 146.70 104.3 143.90 79.82 0.232 
Alcohol, ounces/week 3.68 5.29 3.20 4.26 0.317 
Number of Subjects (N) 1,951 451 
Traits  
Param 
Estimates 
Std. 
Error 
Param 
Estimates 
Std. 
Error 
p-value 
Fasting glucose, mg/dl 96.93 0.23 96.35 0.45 0.266 
FG_adj. change in fasting glucose, mg/dl 2.88 0.31 4.04 0.61 0.097 
     
Incidence of diabetes 4.10% 5.65% 0.141 
176 
 
Appendix 7: Effect of each weighted fasting glucose risk allele on change over time in fasting glucose 
in the full T2DM risk factors-adjusted model. 
Age-, sex-, fasting glucose-adjusted Change in fasting glucose, in mg/dl 
 
Estimate p-value 
Age, years 0.185 <.0001 
Sex, % male 0.805 0.0003 
Fasting glucose, mg/dl -0.417 <.0001 
Mean BP, mmHg, ([2xDBP]+SBP) / 3 0.017 0.054 
BMI, kg/m
2
 0.375 <.0001 
Smoking, % 0.171 0.438 
HDL cholesterol, mg/dl -0.018 0.016 
Triglycerides, mg/dl 0.009 <.0001 
Alcohol, ounces/week -0.015 0.534 
Fasting glucose 16-SNP Genetic Risk Score 0.623  1E-29 
 
 
 
Appendix 8: Mean weighted genetic risk scores in subjects who developed T2DM vs. subjects who 
did not, and additional estimated risk of incident T2DM per weighted risk allele in full T2DM risk 
factors-adjusted models. 
Full T2DM risk factors-
adjusted model 
T2DM No T2DM 
  
Mean *Std. Dev Mean Std. Dev †OR p-value 
Number of Subjects 403 14,997 
  
Age, years 57.87 9.57 51.78 11.18 1.056 <.0001 
Sex, % male 54.74% 45.90% 0.962 0.7546 
Mean BP, mmHG, 
([2xDBP]+SBP) / 3 
99.09 11.58 92.25 11.10 1.138 <.0001 
BMI, kg/m
2
 31.51 5.49 26.61 4.64 1.138 <.0001 
Smoking, % 0.22 0.42 0.25 0.43 1.179 0.2104 
HDL cholesterol, mg/dl 43.66 13.52 51.77 15.27 0.975 <.0001 
Triglycerides, mg/dl 192.80 148.80 120.70 87.92 1.002 <.0001 
Alcohol, ounces/week 2.79 4.64 2.92 4.18 1.000 0.9827 
Mean (CI) T2D 33-SNP Genetic 
Risk Score 
17.25 1.73 16.84 1.71 1.201 4.41E-09 
*Std. Dev: Standard Deviation.  †OR: Odds ratio, per risk-allele. 
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Appendix 9. Interaction effect by fasting glucose-genetic risk score on hypertension, hypertension 
treatment or specific drug exposures  for change over time in fasting glucose in the full set of T2DM 
risk factors-adjusted models. 
 
Interaction_HTNxSNP, multi-adjusted model 
Change in fasting glucose, mg/dl  
Estimate p-value 
Number of subjects 14,490 
Age, years 0.17 <.0001 
Sex, % male 0.84 0.0006 
Fasting glucose, mg/dl -0.42 <.0001 
BMI, kg/m
2
 0.36 <.0001 
Smoking, % 0.22 0.39 
HDL cholesterol, mg/dl -0.02 0.02 
Triglycerides, mg/dl 0.01 1.60E-12 
Alcohol, ounces/week -0.02 0.40 
Hypertension, % 1.04 0.43 
Mean FG 16-SNP Genetic Risk Score 0.62 1.82E-14 
HTN x Mean (CI) FG 16-SNP Genetic Risk Score 0.03 0.85 
   
Interaction_TreatmentxSNP, multi-adjusted model 
Change in fasting glucose, mg/dl 
Estimate p-value 
Number of subjects  4,445 
Age, years 0.12 6.7E-9 
Sex, % male 0.37 0.44 
Fasting glucose, mg/dl -0.28 <.0001 
Mean blood pressure, mmHg (([2xDBP]+SBP) / 3) -0.0057 0.76 
BMI, kg/m
2
 0.33 4.4E-16 
Smoking, % 0.33 0.57 
HDL cholesterol, mg/dl -0.03 0.03 
Triglycerides, mg/dl 0.01 0.0003 
Alcohol, ounces/week -0.07 0.10 
Treated hypertensive  2.06 0.37 
Mean FG 16-SNP GR Score 0.56 0.004 
HTN x Mean (CI) FG GR Score -0.18 0.50 
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Interaction_Beta-blockersxSNP, multi-adjusted model 
Change in fasting glucose, mg/dl 
Estimate p-value 
Number of subjects 4,445 
Age, years 0.11 <.0001 
Sex, % male 0.28 0.55 
Fasting glucose, mg/dl -0.28 <.0001 
Mean blood pressure, mmHg  (([2xDBP]+SBP) / 3) -0.0001 1.00 
BMI, kg/m
2
 0.32 <.0001 
Smoking, % 0.37 0.53 
HDL cholesterol, mg/dl -0.03 0.03 
Triglycerides, mg/dl 0.01 0.0005 
Alcohol, ounces/week -0.07 0.10 
Hypertensive exposed to beta-blockers ONLY 1.27 0.71 
Mean FG 16-SNP Genetic Risk Score 0.56 0.01 
Beta-blockers x Mean (CI) FG 16-SNP Genetic Risk Score -0.11 0.79 
Interaction_ThiazidesxSNP, multi-adjusted model Change in fasting glucose, mg/dl 
Number of subjects 4,445 
Age, years 0,11 <.0001 
Sex, % male 0,28 0,55 
Fasting glucose, mg/dl -0,28 <.0001 
Mean blood pressure, mmHg  (([2xDBP]+SBP) / 3) -0,0001 1,00 
BMI, kg/m
2
 0,32 <.0001 
Smoking, % 0.37 0.53 
HDL cholesterol, mg/dl -0.03 0.03 
Triglycerides, mg/dl 0.01 0.0005 
Alcohol, ounces/week -0.07 0.10 
Hypertensive exposed to thiazides ONLY -0.48 0.90 
Mean FG 16-SNP Genetic Risk Score 0.56 0.01 
Thiazides x Mean (CI) FG 16-SNP Genetic Risk Score -0.04 0.93 
Interaction_ACE-inhibitors/ARBxSNP, multi-adjusted model Change in fasting glucose, mg/dl 
Number of subjects 4,445 
Age, years 0.11 <.0001 
Sex, % male 0.28 0.55 
Fasting glucose, mg/dl -0.28 <.0001 
Mean blood pressure, mmHg  (([2xDBP]+SBP) / 3) -0.0001 1.00 
BMI, kg/m
2
 0.32 <.0001 
Smoking, % 0.37 0.53 
HDL cholesterol, mg/dl -0.03 0.03 
Triglycerides, mg/dl 0.01 0.0005 
Alcohol, ounces/week -0.07 0.10 
Hypertensive exposed toACE-inhibitors/ARB ONLY 3.12 0.45 
Mean FG 16-SNP Genetic Risk Score 0.56 0.01 
ACE-inhibitors/ARB x Mean (CI) FG 16-SNP Genetic Risk Score -0.22 0.64 
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Appendix 10. Interaction effect by T2DM-genetic risk score on hypertension, hypertension treatment 
or specific drug exposures for risk of incident T2DM in the full set of T2DM risk factors -adjusted 
models. 
 
Multi-adjusted model 
T2DM 
OR p-value 
Number of subjects 15,392 (DM=1 N=403) 
Age, years 1.05 2.2E-16 
Sex, % male 1.00 1.00 
BMI, kg/m
2
 1.14 <.0001 
Smoking, % 1.20 0.18 
HDL cholesterol, mg/dl 0.98 3.5E-6 
Triglycerides, mg/dl 1.00 9.8E-8 
Alcohol, ounces/week 1.00 0.88 
Hypertension, % 4.39 0.18 
Mean (CI) T2D 33-SNP  GR Score 1.23 4.7E-5 
HTN x Mean (CI) T2D 33-SNP Genetic Risk Score 0.96 0.50 
Multi-adjusted model 
T2DM 
OR p-value 
Number of subjects 4,757 (DM=1 HTN=1 N=260) 
Age, years 1.03 2.3E-5 
Sex, % male 1.09 0.61 
Mean blood pressure, mmHg (([2xDBP]+SBP) / 3) 1.01 0.27 
BMI, kg/m
2
 1.11 <.0001 
Smoking, % 1.23 0.22 
HDL cholesterol, mg/dl 0.98 0.003 
Triglycerides, mg/dl 1.00 0.0003 
Alcohol, ounces/week 0.98 0.25 
Treated hypertensive  2.80 0.48 
Mean (CI) T2D 33-SNP Genetic Risk Score 1.19 0.01 
HTN_treated x Mean (CI) T2D 33-SNP GR Score 0.97 0.71 
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Multi-adjusted model 
T2DM 
OR p-value 
Number of subjects 4,757 (DM=1 HTN=1 N=260) 
Age, years 1.03 0,0001 
Sex, % male 1.10 0,564 
Mean blood pressure, mmHg (([2xDBP]+SBP) / 3) 1.01 0,283 
BMI, kg/m
2
 1.11 <.0001 
Smoking, % 1.23 0,226 
HDL cholesterol, mg/dl 0.98 0,003 
Triglycerides, mg/dl 1.00 0,0005 
Alcohol, ounces/week 0.98 0,254 
Treated hypertensive  10.76 0,222 
Mean (CI) T2D 33-SNP Genetic Risk Score 1.19 0,013 
Beta-blockers_treated x Mean (CI) T2D 33-SNP GR Score 0.90 0,336 
Multi-adjusted model 
T2DM 
OR p-value 
Number of subjects 4,757 (DM=1 HTN=1 N=260) 
Age, years 1.03 0,0001 
Sex, % male 1.10 0,564 
Mean blood pressure, mmHg (([2xDBP]+SBP) / 3) 1.01 0,283 
BMI, kg/m
2
 1.11 <.0001 
Smoking, % 1.23 0,226 
HDL cholesterol, mg/dl 0.98 0,003 
Triglycerides, mg/dl 1.00 0,0005 
Alcohol, ounces/week 0.98 0,254 
Treated hypertensive  0.61 0,84 
Mean (CI) T2D 33-SNP Genetic Risk Score 1.19 0,013 
Thiazides_treated x Mean (CI) T2D 33-SNP GR Score 1.05 0,72 
Multi-adjusted model 
T2DM 
OR p-value 
Number of subjects 4,757 (DM=1 HTN=1 N=260) 
Age, years 1.03 0,0001 
Sex, % male 1.10 0,564 
Mean blood pressure, mmHg (([2xDBP]+SBP) / 3) 1.01 0,283 
BMI, kg/m
2
 1.11 <.0001 
Smoking, % 1.23 0,226 
HDL cholesterol, mg/dl 0.98 0,003 
Triglycerides, mg/dl 1.00 0,0005 
Alcohol, ounces/week 0.98 0,254 
Treated hypertensive  6.20 0,441 
Mean (CI) T2D 33-SNP Genetic Risk Score 1.19 0,013 
ACE-inhibitors/ARB_treated x Mean (CI) T2D 33-SNP GR Score 0.92 0,531 
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